Board Meetings

January 15, 2025

Agenda	
Agenda	2
Financial and Statistical Reports	
Financial and Statistical Reports NIHD Financial Summary Nov 2024 NIHD Financial Statements Nov 2024 NIHD KPIs FYE 2025 Nov NIHD Financial Update Nov 2024 (1) FYE 2025 Projection Jorie	8 11 15 17 27
Consent Agenda	
Meeting Minutes - December 11, 2024	35 39 45 47 48 50



AGENDA NORTHERN INYO HEALTHCARE DISTRICT BOARD OF DIRECTORS REGULAR MEETING

January 15, 2025, at 5:00 p.m. Northern Inyo Healthcare District invites you to join this meeting:

TO CONNECT VIA ZOOM: (A link is also available on the NIHD Website) https://zoom.us/j/213497015?pwd=TDlIWXRuWjE4T1Y2YVFWbnF2aGk5UT09

Meeting ID: 213 497 015

Password: 608092

PHONE CONNECTION:

888 475 4499 US Toll-free 877 853 5257 US Toll-free Meeting ID: 213 497 015

The Board meets in person at 2957 Birch Street Bishop, CA 93514. Members of the public will be allowed to attend in person or via Zoom. Public comments can be made in person or via Zoom.

Board Member, David McCoy Barrett, will attend from 401 Mercer Street, Seattle, WA 98109, via Zoom.

- 1. Call to Order at 5:00 p.m.
- 2. Public Comment: The purpose of public comment is to allow members of the public to address the Board of Directors. Public comments shall be received at the beginning of the meeting and are limited to three (3) minutes per speaker, with a total time limit of thirty (30) minutes for all public comments unless otherwise modified by the Chair. Speaking time may not be granted and/or loaned to another individual for purposes of extending available speaking time unless arrangements have been made in advance for a large group of speakers to have a spokesperson speak on their behalf. Comments must be kept brief and non-repetitive. The general Public Comment portion of the meeting allows the public to address any item within the jurisdiction of the Board of Directors on matters not appearing on the agenda. Public comments on agenda items should be made at the time each item is considered.
- 3. Public comments on closed session items
- 4. Adjournment to closed session to/for:

- a. Chief of Staff Report Protected by Evidence Code § 1157; Health & Safety Code § 32155
- b. Discuss trade secrets (Health & Safety. Code § 32106 and Civ. Code 3426.1). The discussion will concern a new service line. The estimated date of public disclosure is May 2025.
- c. Public Employee Performance Evaluation pursuant to Government Code Section 54957(b)(1). Title: CEO FY 2025 performance
- 5. Return to open session and report on any actions taken in closed session
- 6. New Business:
 - a. Governance Committee Appointments Action Item
 - b. Chief Executive Officer Report (Board will receive this report)
 - i. Audit
 - ii. Seminar
 - iii. Financial Policies
 - iv. UCSF Alumni Achievement Award Colleen McEvoy
 - c. Chief Financial Officer Report
 - i. Financial & Statistical Reports (Board will consider the approval of these reports)
 - ii. Jorie
 - iii. Finance and Audit Committee meeting update
 - d. Chief of Staff Reports, Sierra Bourne MD
 - i. Dr. Manzanares Family Medicine
 - ii. Medical Executive Committee meeting report
- 7. Consent Agenda All matters listed under the consent agenda are considered routine and will be enacted by one motion unless any member of the Board wishes to remove an item for discussion.
 - a. Approval of minutes of the December 11, 2024 Regular Board Meeting
 - b. CEO Credit Card Statements December 2024
 - c. Approval of Policies and Procedures
 - i. ALARA Program
 - Diagnostic Imaging Handling of Radioactive Packages, Non-nuclear medicine personnel

- iii. Diagnostic Imaging Imaging Equipment Quality Control
- iv. Diagnostic Imaging Patient Priority
- v. Fern Testing
- vi. NIHD Recruitment and Selection Education and Experience Equivalency
- vii. Work Place Violence Prevention Guidelines for Handling Threats or Violent Situations
- 8. General Information from Board Members (*Board will provide this information*)
- 9. Adjournment

In compliance with the Americans with Disabilities Act, if you require special accommodations to participate in a District Board meeting, please contact the administration at (760) 873-2838 at least 24 hours prior to the meeting.



DATE: January 2025

TO: Board of Directors, Northern Inyo Healthcare District

FROM: Andrea Mossman, Chief Financial Officer

RE: Financial Summary and Operation Insights as of November 2024

Financial Summary

- 1. Net Income: November's net loss was \$(251k) which was similar to last year. This was due to lower volumes in the clinics and surgeries. For the year, net income was at \$1.45M due to favorable net revenue caused by increased volume and better payor mix.
- 2. Operating Income: November's operating loss was \$(530k) which was higher than last year due to higher net revenue because of favorable net revenue. For the year, operating loss was better than last fiscal year by \$976k due to increased volume along with reduced expenses.
- 3. EBIDA: November's EBIDA was favorable by \$159k and consistent with prior year. For the year, EBIDA was favorable by \$3.6M.
- 4. Revenue Breakdown: November's inpatient volume and revenue was slightly higher with declines in outpatient due to less surgical volumes. For the year, revenue has increased by 1% due to higher volumes.

Deductions Summary

- 1. Contractual Adjustments: Contractual discounts were higher due to increased gross revenue but were in line with trend when reviewed as a percentage of gross revenue.
- 2. Bad Debt: For November, bad debt declined due to AR >270 days declining by over \$2M. Compared to last November, AR >270 days declined by \$(6.7M).
- 3. Write-offs: Other write-offs were higher than prior year and budget due to aged AR cleanup.

Salaries

1. Per Adjusted Patient Day / Adjusted Employee per Occupied Bed (Adjusted EPOB): For November, wages per patient were higher than last year due to less volume in the outpatient setting. For the year, wages per patient were higher due to increased volume.

- 2. Total Salaries: For November and for the year, wages were higher than last year due to higher pay rate and increase employed FTEs.
- 3. Average Hourly Rate: Average hourly rate was lower than budget and up 2% compare to last year due to merits.

Benefits

- 1. Total Benefits: For November and the year, benefits were lower than last month, budget, or prior year due to reduced medical, dental vision, and federal taxes.
- 2. Benefits % of Wages: For the year, we were at 42% of wages, which was lower than prior year by (11%).

Total Salaries, Wages and Benefits (SWB)

- 1. Salaries, Wages and Benefits (SWB) / Adjusted Patient Day: For the year, we were (13%) under budget and (3%) under prior year-to-date. This was due to higher volume meaning we were more productive.
- 2. Salaries, Wages and Benefits (SWB) % of Total Expenses: For November, we were (12%) lower than budget. For the year, we were lower than budget and prior year. This was due to overall expenses being lower this year. For the year, we were at 51% and our goal was 50%.

Contract Labor

- 1. Contract Labor Expense: For the year, contract labor was 6% higher due to staffing challenges and rates higher than planned.
- 2. Contract Labor Rates: Rates are higher than budgeted by 24%. We will continue to evaluation and negotiate rates based on market.
- 3. Contract Labor Full-Time Equivalents (FTEs): For the year, contract labor is 5% higher than budget or prior year.

Other Expenses

- 1. Physician Expense / Adjusted Patient Day: For the year, physician expenses per patient were (14%) under budget and (16%) under prior year-to-date.
- 2. Supplies: For the year, supplies were lower than prior year-to-date due to lower pharmacy costs.
- 3. Total Expenses: For the year, expenses were under budget by (5%) and under prior year by (1%). This was due to lower benefits along with lower supply expenses.

Stats Summary

- 1. Admits (excluding Nursery): For November, admits were 3% higher. This was due to higher medical admits. For the year, admits were 10% higher due to higher deliveries and medical admits.
- 2. Inpatient Days (excluding Nursery): For November, inpatient days increased 20%. For the year, inpatient days increased 29%.
- 3. Average Daily Census: Average census increased 24% compared to last year-to-date.
- 4. Average Length of Stay (ALOS): Average length of stay increased 13% compared to last year but was still below the maximum for a critical access hospital.
- 5. Deliveries: For the year, Deliveries were 11% higher than last year-to-date.
- Surgical Procedures: For November, surgeries were (13%) under prior year primarily due to
 orthopedics. For the year, surgical procedures were higher by 3% due to urology and general
 surgery.
- 7. Emergency Department (ED) Visits: Emergency visits were higher by 5% compared to last November and higher than last year-to-date by 3% leading to higher medical admits.
- 8. Diagnostic Imaging (DI) Exams: For November, DI exams were slightly lower but for the year, they were up 3%.
- 9. Rehab Visits: Rehab visits were up 60% compared to last year-to-date due to better staffing and corrected billing issues.
- 10. Outpatient Infusion / Injections / Wound Care Visits: These visits were up 35% compared to last year-to-date.
- 11. Observation Hours: Observations hours were down (8%) compared to last year-to-date due to change in observation methodology in the women service line.
- 12. Rural Health Clinic (RHC) Visits: For November, RHC was down (8%) but up for the year by 15 due to behavioral and women.
- 13. Other Clinics: For the year, all clinics increased 16% due to new providers.

Northern Inyo Healthcare District

November 2024 - Financial Summary

		Current	Month		I	Prior MTD			Year to I	Date		Prior YTD			
** Variances are B / (W)	Actual	Budget	Variance	Variance %	Actual	Change	Change %	Actual	Budget	Variance	Variance %	Actual	Change	Change %	
Net Income (Loss)	(250,823)	(1,468,123)	1,217,299	(83%)	(236,090)	(14,733)	(6%)	1,450,539	(4,524,912)	5,975,451	132%	639,798	810,741	127%	
Operating Income (Loss)	(530,332)	(1,738,335)	1,208,003	(69%)	(987,232)	456,900	46%	(355,930)	(6,008,288)	5,652,357	94%	(1,332,337)	976,407	(73%)	
EBIDA (Loss)	158,708	(1,104,545)	1,263,253	(114%)	120,086	38,623	(32%)	3,592,239	(2,707,022)	6,299,260	233%	2,296,144	1,296,094	56%	
IP Gross Revenue	3,654,138	3,449,936	204,203	6%	3,424,188	229,950	7%	18,713,127	17,949,330	763,797	4%	17,266,921	1,446,207	8%	
OP Gross Revenue	12,133,332	13,549,109	(1,415,776)	(10%)	12,912,788	(779,456)	(6%)	73,012,307	71,988,268	1,024,039	1%	68,406,086	4,606,222	7%	
Clinic Gross Revenue	1,695,930	1,703,295	(7,365)	(0%)	1,643,491	52,438	3%	8,817,418	8,248,694	568,725	7%	7,693,507	1,123,912	15%	
Total Gross Revenue	17,483,401	18,702,339	(1,218,939)	(7%)	17,980,468	(497,067)	(3%)	100,542,853	98,186,292	2,356,560	2%	93,366,513	7,176,340	8%	
Net Patient Revenue	9,045,019	8,262,082	782,936	9%	8,294,330	750,689	9%	47,419,442	44,363,995	3,055,446	7%	47,023,968	395,474	1%	
Cash Net Revenue % of Gross	52%	44%	8%	17%	46%	6%	12%	47%	45%	2%	4%	50%	(3%)	(6%)	
Admits (excl. Nursery)	77	75	2	3%	75	2	3%	372	338	34	10%	338	34	10%	
IP Days	245	204	41	20%	204	41	20%	1,324	1,028	296	29%	1,028	296	29%	
IP Days (excl. Nursery)	203	179	24	13%	179	24	13%	1,134	914	220	24%	914	220	24%	
Average Daily Census	6.8	6.0	0.8	13%	6.0	0.8	13%	7.4	6.0	1.4	24%	6.0	1.4	24%	
ALOS	2.6	2.4	0.2	10%	2.4	0.2	10%	3.0	2.7	0.3	13%	2.7	0.3	13%	
Deliveries	14	16	(2)	(13%)	16	(2)	(13%)	89	80	9	11%	80	9	11%	
OP Visits	3,847	3,445	402	12%	3,445	402	12%	19,230	17,055	2,175	13%	17,055	2,175	13%	
Rural Health Clinic Visits	2,203	2,495	(292)	(12%)	2,495	(292)	(12%)	11,476	11,748	(272)		11,748	(272)	(2%)	
Rural Health Women Visits	497	463	34	7%	463	34	7%	2,611	2,340	271	12%	2,340	271	12%	
Rural Health Behavioral Visits	192	178	14	8%	178	14	8%	942	821	121	15%	821	121	15%	
Total RHC Visits	2,892	3,136	(244)	(8%)	3,136	(244)	(8%)	15,029	14,909	120	1%	14,909	120	1%	
Bronco Clinic Visits	43	36	7	19%	36	7	19%	175	105	70	67%	105	70	67%	
Internal Medicine Clinic Visits	-	-	-	-%	-	-	-%	-	201	(201)		201	(201)	(100%)	
Orthopedic Clinic Visits	247	345	(98)	(28%)	345	(98)	(28%)	1,874	1,779	95	5%	1,779	95	5%	
Pediatric Clinic Visits Specialty Clinic Visits	644 509	691 398	(47) 111	(7%) 28%	691 398	(47) 111	(7%) 28%	3,041 2,761	3,058 1,773	(17) 988	(1%) 56%	3,058 1,773	(17) 988	(1%) 56%	
Surgery Clinic Visits	127	133	(6)	(5%)	133	(6)	(5%)	798	607	191	31%	607	191	31%	
Virtual Care Clinic Visits	53	29	24	83%	29	24	83%	301	204	97	48%	204	97	48%	
Total NIA Clinic Visits	1,623	1,632	(9)	(1%)	1,632	(9)	(1%)	8,950	7,727	1,223	16%	7,727	1,223	16%	
IP Surgeries	14	23	(9)	(39%)	23	(9)	(39%)	66	111	(45)		111	(45)	(41%)	
OP Surgeries	115	126	(11)	(9%)	126	(11)	(9%)	674	607	67	11%	607	67	11%	
Total Surgeries	129	149	(20)	(13%)	149	(20)	(13%)	740	718	22	3%	718	22	3%	
Cardiology	-	1	(1)	(100%)	1	(1)	(100%)	3	1	2	200%	1	2	200%	
General	70	56	14	25%	56	14	25%	367	310	57	18%	310	57	18%	
Gynecology & Obstetrics	10	17	(7)	(41%)	17	(7)	(41%)	58	80	(22)	(28%)	80	(22)	(28%)	
Ophthalmology	25	31	(6)	(19%)	31	(6)	(19%)	106	127	(21)	(17%)	127	(21)	(17%)	
Orthopedic	13	30	(17)	(57%)	30	(17)	(57%)	136	145	(9)	(6%)	145	(9)	(6%)	
Pediatric	-	-	-	-%	-	-	-%	-	-	-	-%	-	-	-%	
Plastics	-	-	-	-%	-	-	-%	1	-	1	-%	-	1	-%	
Podiatry	-	-	-	-%	-	-	-%	2	1	1	100%	1	1	100%	
Urology	11	14	(3)	(21%)	14	(3)	(21%)	66	54	12	22%	54	12	22%	
Diagnostic Image Exams	1,880	1,897	(17)	(1%)	1,897	(17)	(1%)	10,577	10,316	261	3%	10,316	261	3%	
Emergency Visits	789	750	39	5%	750	39	5%	4,403	4,265	138	3%	4,265	138	3%	
ED Admits	49	36	13	36%	36	13	36%	217	147	70	48%	147	70	48%	
ED Admits % of ED Visits	6% 903	5%	1% 289	29%	5%	1% 289	29%	5%	3%	1%		3%	1%	43%	
Rehab Visits OP Infusion/Wound Care Visits		614		47% 82%	614		47%	4,459	2,787	1,672	60%	2,787	1,672	60%	
OP Infusion/Wound Care Visits Observation Hours	600 1,017	330 1,949	270 (932)	82% (48%)	330 1,949	270 (932)	82% (48%)	1,993 8,297	1,471 9,017	522 (721)	35% (8%)	1,471 9,017	522 (721)	35%	
Obsci vaudii fiduis	1,017	1,949	(932)	(40%)	1,949	(932)	(40%)	0,297	9,017	(721)	(8%)	9,017	(721)	(8%)	

Northern Inyo Healthcare District

November 2024 – Financial Summary

		Current 1	Month		I	Prior MTD			Year to I	Date		Prior YTD			
** Variances are B / (W)	Actual	Budget	Variance	Variance %	Actual	Change	Change %	Actual	Budget	Variance	Variance %	Actual	Change	Change %	
PAYOR MIX															
Blue Cross	27.7%	20.1%	7.6%	38.1%	20.1%	7.6%	38.1%	26.4%	17.9%	8.5%	47.5%	17.9%	8.5%	47.5%	
Commercial	8.4%	6.9%	1.5%	22.1%	6.9%	1.5%	22.1%	5.4%	3.6%	1.8%	49.7%	3.6%	1.8%	49.7%	
Medicaid	22.3%	30.9%	(8.6%)	(27.7%)	30.9%	(8.6%)	(27.7%)	25.4%	24.0%	1.5%	6.1%	24.0%	1.5%	6.1%	
Medicare	40.4%	40.7%	(0.2%)	(0.6%)	40.7%	(0.2%)	(0.6%)	40.0%	50.5%	(10.5%)	(20.7%)	50.5%	(10.5%)	(20.7%)	
Self-pay	0.6%	1.5%	(0.8%)	(56.3%)	1.5%	(0.8%)	(56.3%)	2.0%	3.4%	(1.4%)	(41.7%)	3.4%	(1.4%)	(41.7%)	
Worker's Comp	0.5%	-%	0.5%	-%	-%	0.5%	-%	0.8%	0.5%	0.2%	45.9%	0.5%	0.2%	45.9%	
Other	-%	-%	-%	-%	-%	-%	-%	-%	0.1%	(0.1%)	(100.0%)	0.1%	(0.1%)	(100.0%)	
DEDUCTIONS															
Contract Adjust	(9,645,351)	(9,200,570)	(444,781)	5%	(8,433,073)	(1,212,277)	14%	(48,614,884)	(47,390,931)	(1,223,953)	3%	(39,962,763)	(8,652,122)	22%	
Bad Debt	2,304,836	(672,129)	2,976,964	(443%)	(957,743)	3,262,579	(341%)	(653,362)	(3,507,947)	2,854,585	(81%)	(3,962,832)	3,309,470	(84%)	
Write-off	(1,097,867)	(567,558)	(530,309)	93%	(295,322)	(802,546)	272%	(3,706,982)	(2,923,419)	(783,563)	27%	(2,418,337)	(1,288,645)	53%	
CENSUS															
Patient Days	203	179	24	13%	179	24	13%	1,134	914	220	24%	914	220	24%	
Adjusted ADC	32	30	2	7%	30	2	7%	40	33	7	22%	32	8	23%	
Adjusted Days	970	940	30	3%	940	30	3%	6,094	4,942	1,152	23%	4,942	1,152	23%	
Employed FTE	364.7	350.6	14.2	4%	350.6	14.2	4%	362.9	355.6	7.2	2%	355.6	7.2	2%	
Contract Labor FTE	23.6	27.1	(3.5)	(13%)	27.1	(3.5)	(13%)	26.8	25.4	1.4	5%	25.4	1.4	5%	
Total Paid FTE	388.3	377.7	10.6	3%	377.7	10.6	3%	389.6	381.0	8.6	2%	381.0	8.6	2%	
EPOB (Employee per Occupied Bed)	1.9	2.1	(0.2)	(9%)	2.1	(0.2)	(9%)	1.8	2.1	(0.4)	(18%)	2.1	(0.4)	(18%)	
EPOC (Employee per Occupied Case)	0.4	0.4	(0.0)	(4%)	0.4	(0.0)	(4%)	0.1	0.1	(0.0)	(17%)	0.1	(0.0)	(17%)	
Adjusted EPOB	9.2	11.1	(1.9)	(,	11.1	(1.9)	(17%)	9.4	11.5	(2.1)	(18%)	11.5	(2.1)	(18%)	
Adjusted EPOC	1.9	2.2	(0.3)	(12%)	2.2	(0.3)	(12%)	0.3	0.4	(0.1)	(18%)	0.4	(0.1)	(18%)	
SALARIES															
Per Adjust Bed Day	3,570	3,686	(116)	(3%)	3,327	243	7%	2,799	3,553	(754)	(21%)	3,302	(503)	(15%)	
Total Salaries	3,463,941	3,464,324	(384)	(0%)	3,126,785	337,155	11%	17,058,398	17,558,435	(500,037)	(3%)	16,318,043	740,355	5%	
Average Hourly Rate	55.40	57.65	(2.24)	(4%)	52.03	3.37	6%	53.77	56.47	(2.70)	(5%)	52.48	1.29	2%	
Employed Paid FTEs	364.7	350.6	14.2	336.4	350.6	14.2	4%	362.9	355.6	7.2	2%	355.6	7.2	2%	
<u>BENEFITS</u>															
Per Adjust Bed Day	735	2,192	(1,457)	(66%)	1,920	(1,185)	(62%)	1,187	2,095	(908)	(43%)	1,779	(592)	(33%)	
Total Benefits	713,356	2,060,105	(1,346,749)	(65%)	1,804,521	(1,091,165)	(60%)	7,231,310	10,352,339	(3,121,030)	(30%)	8,790,344	(1,559,035)	(18%)	
Benefits % of Wages	21%	59%	(39%)	(65%)	58%	-37%	(64%)	42%	59%	(17%)	(28%)	54%	(11%)	(21%)	
Pension Expense	376,674	497,683	(121,009)	(24%)	330,787	45,887	14%	2,045,151	2,489,818	(444,666)	(18%)	2,120,181	(75,030)	(4%)	
MDV Expense	184,740	748,612	(563,872)	(75%)	1,146,839	(962,099)	(84%)	3,643,074	3,743,060	(99,986)	(3%)	5,151,198	(1,508,124)	(29%)	
Taxes, PTO accrued, Other	151,942	813,811	(661,868)	(81%)	326,894	(174,952)	(54%)	1,543,085	4,119,462	(2,576,377)	(63%)	1,518,966	24,119	2%	
Salaries, Wages & Benefits	4,177,297	5,524,430	(1,347,133)	(24%)	4,931,306	(754,009)	(15%)	24,289,707	27,910,774	(3,621,067)	(13%)	25,108,387	(818,679)	(3%)	
SWB/APD	4,305	5,877	(1,573)	(27%)	5,246	(942)	(18%)	3,986	5,647	(1,662)	(29%)	5,080	(1,095)	(22%)	
SWB % of Total Expenses	44%	55%	(12%)	(21%)	53%	(10%)	(18%)	51%	55%	(5%)	(8%)	52%	(1%)	(2%)	

Northern Inyo Healthcare District

November 2024 – Financial Summary

		Current 1	Month		I	rior MTD			Year to	Date		Prior YTD			
** Variances are B / (W)	Actual	Budget	Variance	Variance %	Actual	Change	Change %	Actual	Budget	Variance	Variance %	Actual	Change	Change %	
PROFESSIONAL FEES															
Per Adjust Bed Day	2,656	2,394	261	11%	2,352	304	13%	2,037	2,266	(229)	(10%)	2,486	(449)	(18%)	
Total Physician Fee	1,508,531	1,463,822	44,708	3%	1,713,978	(205,447)	(12%)	7,782,174	7,317,511	464,663	6%	7,476,902	305,272	4%	
Total Contract Labor	583,367	374,560	208,807	56%	211,163	372,204	176%	2,351,817	1,796,420	555,397	31%	2,211,088	140,729	6%	
Total Other Pro-Fees	485,226	412,013	73,214	18%	285,601	199,625	70%	2,282,063	2,085,368	196,696	9%	2,600,834	(318,771)	(12%)	
Total Professional Fees	2,577,124	2,250,395	326,729	15%	2,210,742	366,382	17%	12,416,054	11,199,299	1,216,756	11%	12,288,824	127,230	1%	
Contract AHR	144.39	80.59	63.80	79%	45.43	98.96	218%	100.44	80.86	19.58	24%	99.52	0.91	1%	
Contract Paid FTEs	23.6	27.1	(3.5)	(13%)	27.1	(3.5)	(13%)	26.8	25.4	1.4	5%	25.4	1.4	5%	
Physician Fee per Adjust Bed Day	1,555	1,557	(3)	(0%)	1,824	(269)	(15%)	1,277	1,481	(204)	(14%)	1,513	(236)	(16%)	
PHARMACY															
Per Adjust Bed Day	648	491	157	32%	462	186	40%	274	467	(193)	(41%)	434	(160)	(37%)	
Total Rx Expense	628,990	461,460	167,530	36%	434,409	194,581	45%	1,669,046	2,307,298	(638,252)	(28%)	2,146,253	(477,207)	(22%)	
MEDICAL SUPPLIES															
Per Adjust Bed Day	418	458	(40)	(9%)	449	(31)	(7%)	407	434	(28)	(6%)	504	(97)	(19%)	
Total Medical Supplies	405,863	430,271	(24,409)	(6%)	421,832	(15,969)	(4%)	2,478,139	2,146,155	331,984	15%	2,489,484	(11,345)	(0%)	
EHR SYSTEM															
Per Adjust Bed Day	49	144	(95)	(66%)	(1)	50	(4,183%)	31	137	(106)	(77%)	111	(80)	(72%)	
Total EHR Expense	47,276	135,000	(87,724)	(65%)	(1,122)	48,398	(4,315%)	187,739	675,000	(487,261)	(72%)	547,759	(360,020)	(66%)	
OTHER EXPENSE															
Per Adjust Bed Day	1,370	889	481	54%	988	382	39%	754	873	(120)	(14%)	833	(80)	(10%)	
Total Other	1,329,269	835,283	493,986	59%	928,219	401,050	43%	4,592,987	4,315,866	277,120	6%	4,119,252	473,734	12%	
DEPRECIATION AND AMORTIZATION															
Per Adjust Bed Day	422	387	35	9%	379	43	11%	351	368	(16)	(4%)	335	16	5%	
Total Depreciation and Amortization	409,531	363,578	45,953	13%	356,176	53,355	15%	2,141,699	1,817,890	323,809	18%	1,656,346	485,353	29%	
TOTAL EXPENSES	9,575,350	10.000.417	(425,067)	(4%)	9,281,562	293,789	3%	47,775,372	50,372,283	(2,596,911)	(5%)	48,356,305	(580,933)	(1%)	
Per Adjust Bed Day	9,373,330	10,000,417	(772)	(7%)	9,281,302	293,789	(0%)	7,839	10,192	(2,353)	(23%)	9,784	(1,945)	(20%)	
Per Calendar Day	319,178	333,347	(14,169)	(4%)	309,385	9,793	3%	312,257	329,231	(16,973)	(5%)	316,054	(3,797)	(1%)	
i di Caldidai Day	317,170	333,347	(14,109)	(+70)	202,203	7,173	J 70	314,437	347,431	(10,9/3)	(3%)	310,034	(3,191)	(170)	

Northern Inyo Healthcare District Income Statement Fiscal Year 2025

Fiscal Year 2025								
	11/30/2024	Nov Budget	11/30/2023	2025 YTD	2024 YTD	Budget Variance	PYM Change	PYTD Change
Gross Patient Service Revenue								
Inpatient Patient Revenue	3,654,138	3,449,936	3,424,188	18,713,127	17,266,921	204,203	229,950	1,446,207
Outpatient Revenue	12,133,332	13,549,109	12,912,788	73,012,307	68,406,086	(1,415,776)	(779,456)	4,606,222
Clinic Revenue	1,695,930	1,703,295	1,643,491	8,817,418	7,693,507	(7,365)	52,438	1,123,912
Gross Patient Service Revenue	17,483,401	18,702,339	17,980,468	100,542,853	93,366,513	(1,218,939)	(497,067)	7,176,340
Deductions from Revenue						-		-
Contractual Adjustments	(9,645,351)	(9,200,570)	(8,433,073)	(48,614,884)	(39,962,763)	(444,781)	(1,212,277)	(8,652,122)
Bad Debt	2,304,836	(672,129)	(957,743)	(653,362)	(3,962,832)	2,976,964	3,262,579	3,309,470
A/R Writeoffs	(1,097,867)	(567,558)	(295,322)	(3,706,982)	(2,418,337)	(530,309)	(802,546)	(1,288,645)
Other Deductions from Revenue	-	-	-	(152,618)	-	-	-	(152,618)
Deductions from Revenue	(8,438,382)	(10,440,257)	(9,686,138)	(53,127,846)	(46,343,932)	2,001,875	1,247,756	(6,783,914)
Other Patient Revenue								-
Incentive Income	-	-	-	2,000	-	-	-	2,000
Other Oper Rev - Rehab Thera Serv	-	-	-	2,435	1,387	-	-	1,048
Medical Office Net Revenue	-	-	-	-	-	-	-	-
Other Patient Revenue	-	-	-	4,435	1,387	-	-	3,048
Net Patient Service Revenue	9,045,019	8,262,082	8,294,330	47,419,442	47,023,968	782,936	750,689	395,474
CNR%	51.7%	44.2%	46.1%	47.2%	50.4%	-0.6%	-1.9%	-3.2%
Cost of Services - Direct								-
Salaries and Wages	2,944,227	2,944,553	2,694,788	14,386,323	14,038,148	(326)	249,439	348,175
Benefits	616,715	1,781,015	1,536,819	6,170,377	7,522,009	(1,164,300)	(920,104)	(1,351,632)
Professional Fees	1,764,851	1,660,468	1,875,536	8,957,315	8,814,424	104,383	(110,685)	142,892
Contract Labor	495,129	317,906	263,663	2,031,480	1,997,523	177,223	231,465	33,957
Pharmacy	628,990	461,460	434,409	1,669,046	2,146,253	167,530	194,581	(477,207)
Medical Supplies	405,863	430,271	421,832	2,478,139	2,489,484	(24,409)	(15,969)	(11,345)
Hospice Operations	´-	´-	_	, , , , , , , , , , , , , , , , , , ,	· -	`	` -	`
EHR System Expense	47,276	135,000	(1,122)	187,739	547,759	(87,724)	48,398	(360,020)
Other Direct Expenses	848,957	533,466	695,124	3,414,019	3,209,702	315,491	153,833	204,317
Total Cost of Services - Direct	7,752,007	8,264,138	7,921,050	39,294,438	40,765,302	(512,130)	(169,042)	(1,470,864)
	.,,	0,20 1,100	.,,		,,	(===,===)	(,)	(-,,)
General and Administrative Overhead								
Salaries and Wages	519,714	519,772	431,997	2,672,075	2,279,895	(58)	87,717	392,180
Benefits	96,641	279,090	267,702	1,060,933	1,268,335	(182,449)	(171,061)	(207,402)
Professional Fees	228,906	215,367	124,043	1,106,922	1,263,313	13,539	104,863	(156,391)
Contract Labor	88,238	56,655	(52,500)	320,337	213,565	31,583	140,738	106,772
Depreciation and Amortization	409,531	363,578	356,176	2,141,699	1,656,346	45,953	53,355	485,353
Other Administative Expenses	480,312	301,818	233,094	1,178,967	909,550	178,495	247,218	269,418
Total General and Administrative Overhead	1,823,343	1,736,279	1,360,512	8,480,934	7,591,003	87,064	462,831	889,930
Total Expenses	9,575,350	10,000,417	9,281,562	47,775,372	48,356,305	(425,067)	293,789	(580,933)
Total Expenses	7,575,550	10,000,417	7,201,502	41,113,312	40,000,000	(423,007)	273,767	(500,755)
Financing Expense	206,574	185,154	182,866	1,003,930	898,283	21,420	23,708	105,647
Financing Income	181,031	238,960	228,125	1,222,661	1,140,623	(57,930)	(47,094)	82,039
Investment Income	56,648	46,181	324,800	240,084	658,157	10,467	(268,152)	(418,073)
Miscellaneous Income	248,404	170,225	381,083	1,347,654	1,071,639	78,179	(132,679)	276,015
Net Income (Change in Financial Position)	(250,823)	(1,468,123)	(236,090)	1,347,634	639,798	1,217,299	(132,679)	810,741
			` / /	/ /				
Operating Income	(530,332)	(1,738,335)	(987,232)	(355,930)	(1,332,337)	1,208,003	456,900	976,407
EBIDA	158,708	(1,104,545)	120,086	3,592,239	2,296,144	1,263,253	38,623	1,296,094
Net Profit Margin	-2.8%	-17.8%	-2.8%	3.1%	1.4%	15.0%	0.1%	1.7%

Current Assets Curr	Fiscal Year 2025		0.00.00.00	0.000.000	10/21/2021	40/24/2022	44.00.00.004	44/20/2022	T. C.	****
Cash and Liquid Capital 18,718.414 17,374.679 18,771.541 16,999.078 15,130.616 10,295.002 9,784.681 (6,614.056) 310.23		PY Balances	9/30/2024	9/30/2023	10/31/2024	10/31/2023	11/30/2024	11/30/2023	PM Change	PY Change
Cash and Liquid Capital 18,718,414 17,374,679 18,771,541 19,955 35,030 15,130,161 10,255,002 9,784,681 (6,64),256 10,128,521 10,285,012										
Short Term Investments		10.710.414	15.054.650	10.551.541	16000.050	15 100 616	10.205.002	0.704.601	(6.614.056)	510.001
PMA Partnership	1 1									
Control Receivable 1,792-1,674 19,842,488 15,119.99 18,105.429 18,105.629 12,051.239 20,046,355 1,348,860 (06.25 1,348,860 1,3		6,418,451	7,574,716	10,555,533	6,876,555	10,658,191	6,872,978	8,158,191	(3,577)	(1,285,213)
Deferment 1,754,052 4,833,782 794,881 4,771,477 1,194,140 9,458,1405 2,837,260 4,686,628 6,620,84 Peppali Expenses 1,119,559 1,933,055 2,332,6125 1,353,383 2,327,751 1,102,300 2,229,168 (251,083) 1,166,58 Total Current Assets		-	-	-	-	-	-	-	-	-
Prepair Expenses	· · · · · · · · · · · · · · · · · · ·								, , , , , , , , , , , , , , , , , , ,	. , ,
Prepad Expenses 1.119.559 1.933.935 2.326.052 1.353.383 2.377.751 1.102.000 2.269.168 (25.10.83) (1.166.86 Total Current Habilities 1.119.559 1.933.935 52.722.787 54.695.348 52.993.660 53.990.075 48.721.807 (795.270) 5175.207 57.00									, , , , , , , , , , , , , , , , , , ,	, ,
Asset Limited as to Use 1,467,786 1,468,166 1,466,663 1,468,293 1,466,789 1,468,417 1,466,910 1,24 1,50	•									
Internally Designated for Capital Acquisition 1,467,786 1,468,166 1,466,663 1,468,293 1,468,497 1,468,417 1,466,910 1,24 1,55 1,25 1			, ,				, ,			(1,166,869)
Short Term Restricted 1,467,786 1,468,166 1,466,663 1,466,793 1,466,789 1,468,417 1,466,910 124 1,50 1,467,786 1,468,166 1,466,663 1,466,893 1,468,417 1,466,910 124 1,50 1,467,786 1,467,786 1,468,169 1,366,409 13,076,830 13,076,83		55,038,873	57,662,375	52,722,787	54,695,345	52,939,560	53,900,075	48,721,807	(795,270)	5,178,268
Short Tem - Restricted 1,467,786 1,468,166 1,466,663 1,468,293 1,466,789 1,468,417 1,466,910 1,24 1,55 1,24 1,2										
Lalife IOC Pension Board Restricted LAIF - IOC Pension Deferred Outflow - Excess Acquisition Service 1975 - 100 -			-	-	-		-			-
LAIF- DC Pension Board Restricted LAIF- DB Pension Board Restricted 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 13,076,830 10,346,490 13,076,830 13		1,467,786	1,468,166	1,466,663	1,468,293	1,466,789	1,468,417	1,466,910	124	1,507
LAIF - DB Pension Board Restricted 10,346,490 10,346,490 13,076,830 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 13,076,830 10,346,490 13,076,830 13,076,830 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 10,346,490 13,076,830 13,07									-	-
PEPRA Pension Deferred Outflow- Excess Acquisition 573,097 573		-	-		-		-	,	-	(828,417)
PEPRA Pension Deferred Outflow - Excess Acquisition T33.097 S73.097		10,346,490	10,346,490	13,076,830	10,346,490	13,076,830	10,346,490	13,076,830	-	(2,730,340)
Deferred Outflow - Excess Acquisition 737.097 737.	PEPRA - Deferred Outflows	-	-	-	-		-	-	-	-
Total Limited Use Assets 10,919,587 10,919,587 14,478,346 10,919,587 14,478,344 - 3,558,75	PEPRA Pension	-	-	-	-		-	-	-	-
Revenue Bonds Held by a Trustee 376,411 359,303 752,501 353,592 746,796 347,848 760,392 (5,744) (412,54 Long Term Assets 1,2763,784 12,747,856 16,697,511 12,741,473 16,118,832 12,735,852 16,705,646 (5,620) 3,969,79	Deferred Outflow - Excess Acquisition	573,097	573,097	573,097	573,097		573,097	573,097	-	-
Total Assets Limited as to Use 12,763,784 12,747,056 16,697,511 12,741,473 16,118,832 12,735,852 16,705,646 (5,620) (3,969,79)	Total Limited Use Assets	10,919,587	10,919,587	14,478,346	10,919,587	13,905,247	10,919,587	14,478,344	-	(3,558,757)
Long Term Investment	Revenue Bonds Held by a Trustee	376,411	359,303	752,501	353,592	746,796	347,848	760,392	(5,744)	(412,544)
Ling Term Investment 1,846,138 755,869 2,790,423 999,950 2,797,561 747,654 3,057,305 (252,296) (2,309,656)	Total Assets Limited as to Use	12,763,784	12,747,056	16,697,511	12,741,473	16,118,832	12,735,852	16,705,646	(5,620)	(3,969,794)
Fixed Assets, Net of Depreciation 84.474,743 84.066.999 76.854.908 83.828.939 77.676.251 83.555.961 77.109.988 (272.978) 6.445.97 Total Long Term Assets 154,123.537 155,232.299 149.065.629 152.265.708 149.532.205 150.393.543 145.594.746 (1,326.165) 5.344.716 Current Liabilities Current Maturities of Long-Term Debt 4.146.183 4.771.637 190.197 4.782.382 655.101 4.744.967 676.353 (37.415) 4.068.61 Accounts Payable 5.010.089 4.443.274 6.935.344 3.949.738 6.819.778 4.373.497 5.370.018 387.759 (1.921.655) Accrued Interest and Sales Tax 109.159 78.276 96.606 166.606 166.957 192.433 240.254 25.832 (47.82 48.84 48.600 46.680 16.33.708 44.6860 1.633.	Long Term Assets									
Total Long Term Assets 86,320,881 84,822,868 79,645,331 84,828,890 80,473,812 84,303,615 80,167,293 (525,274) 4,136,32 Labilities (1,326,165 5,344,79 152,322,299 149,065,629 152,265,708 149,532,205 159,395,543 145,594,746 (1,326,165 5,344,79 120,1011 140,1011	Long Term Investment	1,846,138	755,869	2,790,423	999,950	2,797,561	747,654	3,057,305	(252,296)	(2,309,651)
Total Assets 154,123,537 155,232,299 149,065,629 152,265,708 149,532,205 150,939,543 145,594,746 (1,326,165) 5,344,79	Fixed Assets, Net of Depreciation	84,474,743	84,066,999	76,854,908	83,828,939	77,676,251	83,555,961	77,109,988	(272,978)	6,445,973
Liabilities Current Liabilities Current Maturities of Long-Term Debt 4,146,183 4,771,637 190,197 4,782,382 655,101 4,744,967 676,353 (37,415) 4,068,61 Accounts Payable 5,010,089 4,443,274 6,935,344 3,949,738 6,819,778 4,337,497 5,370,018 387,759 (1,032,52) Accrued Payroll and Related 6,224,657 4,915,339 12,664,353 5,437,529 12,669,463 3,515,873 8,534,376 (1,921,655) (1,932,654) (1,921,655) (1,932,654) (1,921,655) (1,932,654) (1,921,655) (1,932,654) (1,921,655) (1,932,654) (1,921,655) (1,932,654) (1,921,655) (1,932,654) (1,921,655) (1,932,654) (1,921,655) (1,932,654) (1,921,655) (1,932,654) (1,921,655) (1,932,654) (1,	Total Long Term Assets	86,320,881	84,822,868	79,645,331	84,828,890	80,473,812	84,303,615	80,167,293	(525,274)	4,136,322
Current Liabilities Current Maturities of Long-Term Debt 4,146,183 4,771,637 190,197 4,782,382 655,101 4,744,967 676,333 (37,415) 4,068,61 Accorned Payroll and Related 6,224,657 4,915,339 12,664,513 5,437,529 12,669,463 3,515,873 8,534,376 (1,921,655) (5,018,50) Accrued Interest and Sales Tax 109,159 78,276 66,606 166,600 166,597 192,433 240,254 25,832 (47,82) Notes Payable 446,860 446,860 1,633,708 446,860 1,633,708 446,860 1,633,708 446,860 1,633,708 446,860 1,633,708 - (1,186,84) Une tor Strephylory 693,247 <td< td=""><td>Total Assets</td><td>154,123,537</td><td>155,232,299</td><td>149,065,629</td><td>152,265,708</td><td>149,532,205</td><td>150,939,543</td><td>145,594,746</td><td>(1,326,165)</td><td>5,344,797</td></td<>	Total Assets	154,123,537	155,232,299	149,065,629	152,265,708	149,532,205	150,939,543	145,594,746	(1,326,165)	5,344,797
Current Maturities of Long-Term Debt A,146,183 A,771,637 Accounte Payable 5,010,089 A,443,274 6,935,344 3,949,738 6,819,778 6,819,778 Accrued Payroll and Related 6,224,657 Accrued Interest and Sales Tax 109,159 78,276 Notes Payable 446,860 1,633,708 Ade,860 1,66,600 1,66,600 1,66,957 1,92,433 1,92,254 2,5,832 1,647,82 Notes Payable 1,64,542 1,	Liabilities									
Accounts Payable 5,010,089 4,443,274 6,935,344 3,949,738 6,819,778 4,337,497 5,370,018 387,759 (1,032,52 Accrued Payroll and Related 6,224,657 4,915,339 12,664,513 5,437,529 12,666,600 166,6957 192,433 240,254 25,832 (47,82 Notes Payable 446,860 446,860 1,633,708 1,633,708 1,7599,409 1,7599,40	Current Liabilities									
Accrued Payroll and Related Accrued Payroll and Related Accrued Interest and Sales Tax 109,159 78,276 96,606 166,600 166,957 192,433 240,254 25,832 (47,82) 109,159 Notes Payable Unearmed Revenue (4,542) (4,542) (4,542) (4,542) 10,4542) 10,4542 10,4542) 10,4542 10,4542) 10,4542 10,4542) 10,4542 10,4542) 10,4542 10,4542) 10,4542 10,4542) 10,4542 10,4542 10,4542) 10,4542 10,	Current Maturities of Long-Term Debt	4,146,183	4,771,637	190,197	4,782,382	655,101	4,744,967	676,353	(37,415)	4,068,614
Accrued Interest and Sales Tax 109,159 78,276 96,606 166,600 166,957 192,433 240,254 25,832 (47,82 Notes Payable 446,860 446,860 1,633,708 446,860 1,633,708 446,860 1,633,708 - (1,186,84 Unearmed Revenue (4,542) (4	Accounts Payable	5,010,089	4,443,274	6,935,344	3,949,738	6,819,778	4,337,497	5,370,018	387,759	(1,032,521)
Notes Payable 446,860 446,860 1,633,708 446,860 1,633,708 446,860 1,633,708 446,860 1,633,708 Uncarned Revenue (4,542)	Accrued Payroll and Related	6,224,657	4,915,339	12,664,513	5,437,529	12,669,463	3,515,873	8,534,376	(1,921,655)	(5,018,503)
Notes Payable 446,860 446,860 1,633,708 446,860 1,633,708 446,860 1,633,708 446,860 1,633,708 Uncarned Revenue (4,542)	Accrued Interest and Sales Tax	109,159	78,276	96,606	166,600	166,957	192,433	240,254	25,832	(47,821)
Uneamed Revenue (4,542) (4,542) (4,542) (4,542) (4,542) (4,542) (4,542) (4,542) (4,542) - Due to 3rd Party Payors 693,247 693,									´-	(1,186,847)
Due to 3rd Party Payors Due to Specific Purpose Funds Other Deferred Credits - Pension & Leases Total Current Liabilities Long Term Debt Total Long Term Liabilities Due to Specific Purpose Funds Superse Liabilities		(4,542)	(4,542)	(4,542)	(4,542)	(4,542)	(4,542)	(4,542)	_	- 1
Due to Specific Purpose Funds 12,599,823 12,593,614 1,873,995 12,591,545 1,873,995 12,589,475 1,873,995 12,589,475 1,873,995 1,901,740 1,901,7409 1,901	Due to 3rd Party Payors	693,247		693,247					_	_
Other Deferred Credits - Pension & Leases 12,599,823 12,593,614 1,873,995 12,591,545 1,873,995 12,589,475 1,873,995 (2,070) 10,715,488 Total Current Liabilities 29,225,475 27,937,705 24,083,068 28,063,360 24,507,707 26,515,810 19,017,409 (1,547,549) 7,498,40 Long Term Debt 36,301,355 36,004,290 33,341,647 34,797,823 32,730,530 34,698,029 31,715,530 (99,794) 2,982,49 Bond Premium 165,618 156,207 193,852 153,070 190,715 149,933 187,578 (3,137) (37,64 Accreted Interest 16,991,065 17,271,137 17,409,141 16,560,403 17,504,273 16,653,761 17,599,405 93,358 (945,64 Other Non-Current Liabilities 86,404,394 86,377,989 98,202,303 84,457,651 97,683,181 84,448,078 96,760,176 (9,573) (12,312,09 Suspense Liabilities 31,506 147,821 36,944 127,821 68,644 127,821 107,118		-	<u>-</u>	-	-	_	_	-	_	_
Total Current Liabilities 29,225,475 27,937,705 24,083,068 28,063,360 24,507,707 26,515,810 19,017,409 (1,547,549) 7,498,40 Long Term Liabilities Long Term Debt 36,301,355 36,004,290 33,341,647 34,797,823 32,730,530 34,698,029 31,715,530 (99,794) 2,982,49 Bond Premium 165,618 156,0207 193,852 153,070 190,715 149,933 187,578 (3,137) (37,64 Accreted Interest 16,991,065 17,271,137 17,409,141 16,560,403 17,504,273 16,653,761 17,599,405 93,358 (945,64 Other Non-Current Liability - Pension 32,946,355 32,946,355 47,257,663 32,946,355 47,257,663 32,946,355 47,257,663 32,946,355 47,257,663 - (14,311,30) Total Long Term Liabilities 86,404,394 86,377,989 98,202,303 84,457,651 97,683,181 84,448,078 96,760,176 (9,573) (12,312,09) Suspense Liabilities 115,661,375 114,463,515 122,322,315 112		12,599,823	12,593,614	1.873.995	12,591,545	1.873.995	12,589,475	1.873.995	(2.070)	10,715,480
Long Term Liabilities	•								. , ,	7,498,401
Long Term Debt 36,301,355 36,004,290 33,341,647 34,797,823 32,730,530 34,698,029 31,715,530 (99,794) 2,982,49 Bond Premium 165,618 156,207 193,852 153,070 190,715 149,933 187,578 (3,137) (37,64 Accreted Interest 16,991,065 17,271,137 17,409,141 16,560,403 17,504,273 16,653,761 17,599,405 93,358 (945,64 Other Non-Current Liability - Pension 32,946,355 32,946,355 47,257,663				,,,,,,,,	,,	,,	,	,,	(=,= ::,= :-)	.,,
Bond Premium 165,618 156,207 193,852 153,070 190,715 149,933 187,578 (3,137) (37,64) Accreted Interest 16,991,065 17,271,137 17,409,141 16,560,403 17,504,273 16,653,761 17,599,405 93,358 (945,64) Other Non-Current Liability - Pension 32,946,355 32,946,355 47,257,663 32,946,355 47,257,663 32,946,355 47,257,663 32,946,355 47,257,663 - (14,311,30)		36 301 355	36 004 290	33 341 647	34 797 823	32 730 530	34 698 029	31 715 530	(99 794)	2 982 499
Accreted Interest 16,991,065 17,271,137 17,409,141 16,560,403 17,504,273 16,653,761 17,599,405 93,358 (945,64 Other Non-Current Liability - Pension 32,946,355 32,946,355 47,257,663 47,257,663 47,257										(37,645)
Other Non-Current Liability - Pension 32,946,355 32,946,355 47,257,663 32,946,355 47,257,663 32,946,355 47,257,663 32,946,355 47,257,663 32,946,355 47,257,663 47,257,663 - (14,311,30) Total Long Term Liabilities 86,404,394 86,377,989 98,202,303 84,457,651 97,683,181 84,448,078 96,760,176 (9,573) (12,312,09) Suspense Liabilities 1 31,506 147,821 36,944 127,821 68,644 127,821 107,118 - 20,70 Total Liabilities 115,661,375 114,463,515 122,322,315 112,648,832 122,259,532 111,091,709 115,884,703 (1,557,122) (4,792,99) Fund Balance 31,992,031 36,994,377 23,268,194 36,447,220 23,786,064 36,928,877 26,459,404 481,657 10,469,47 Temporarily Restricted 1,467,786 1,468,166 2,610,594 1,468,293 2,610,720 1,468,417 2,610,841 124 (1,124,42) Net Income 5,002,346 2,306,242								,		(945,644)
Total Long Term Liabilities 86,404,394 86,377,989 98,202,303 84,457,651 97,683,181 84,448,078 96,760,176 (9,573) (12,312,09 Suspense Liabilities Uncategorized Liabilities (grants) 31,506 147,821 36,944 127,821 68,644 127,821 107,118 - 20,70 Total Liabilities 115,661,375 114,463,515 122,322,315 112,648,832 122,259,532 111,091,709 115,884,703 (1,557,122) (4,792,99 Fund Balance 31,992,031 36,994,377 23,268,194 36,447,220 23,786,064 36,928,877 26,459,404 481,657 10,469,47 Temporarily Restricted 1,467,786 1,468,166 2,610,594 1,468,293 2,610,720 1,468,417 2,610,841 124 (1,142,42 Net Income 5,002,346 2,306,242 864,526 1,701,362 875,889 1,450,539 639,798 (250,823) 810,74 Total Fund Balance 38,462,163 40,768,784 26,743,313 39,616,876 27,272,672 39,847,834									-	. , ,
Suspense Liabilities Uncategorized Liabilities (grants) 31,506 147,821 36,944 127,821 68,644 127,821 107,118 - 20,70 Total Liabilities 115,661,375 114,463,515 122,322,315 112,648,832 122,259,532 111,091,709 115,884,703 (1,557,122) (4,792,99 Fund Balance Fund Balance Fund Balance 31,992,031 36,994,377 23,268,194 36,447,220 23,786,064 36,928,877 26,459,404 481,657 10,469,47 Temporarily Restricted 1,467,786 1,468,166 2,610,594 1,468,293 2,610,720 1,468,417 2,610,841 124 (1,142,42 Net Income 5,002,346 2,306,242 864,526 1,701,362 875,889 1,450,539 639,798 (250,823) 810,74 Total Fund Balance 38,462,163 40,768,784 26,743,313 39,616,876 27,272,672 39,847,834 29,710,043 230,958 10,137,79 Liabilities + Fund Balance 154,123,537 155,232,299 149,065,629 152,265,708 149,532,205 150,939,543 145,594,746 (1,326,165) 5,344,79					, ,		, ,		(9 573)	
Uncategorized Liabilities (grants) 31,506 147,821 36,944 127,821 68,644 127,821 107,118 - 20,70 Total Liabilities 115,661,375 114,463,515 122,322,315 112,648,832 122,259,532 111,091,709 115,884,703 (1,557,122) (4,792,99 Fund Balance Fund Balance 31,992,031 36,994,377 23,268,194 36,447,220 23,786,064 36,928,877 26,459,404 481,657 10,469,47 Temporarily Restricted 1,467,786 1,468,166 2,610,594 1,468,293 2,610,720 1,468,417 2,610,841 124 (1,142,42 Net Income 5,002,346 2,306,242 864,526 1,701,362 875,889 1,450,539 639,798 (250,823) 810,74 Total Fund Balance 38,462,163 40,768,784 26,743,313 39,616,876 27,272,672 39,847,834 29,710,043 230,958 10,137,79 Liabilities + Fund Balance 154,123,537 155,232,299 149,065,629 152,265,708 149,532,205 150,939,543		-	-	70,202,505	04,437,031	77,005,101	-	20,700,170	(),575)	(12,512,070)
Total Liabilities 115,661,375 114,463,515 122,322,315 112,648,832 122,259,532 111,091,709 115,884,703 (1,557,122) (4,792,99 Fund Balance Fund Balance 31,992,031 36,994,377 23,268,194 36,447,220 23,786,064 36,928,877 26,459,404 481,657 10,469,47 Temporarily Restricted 1,467,786 1,468,166 2,610,594 1,468,293 2,610,720 1,468,417 2,610,841 124 (1,142,42 Net Income 5,002,346 2,306,242 864,526 1,701,362 875,889 1,450,539 63,798 (250,823) 810,74 Total Fund Balance 38,462,163 40,768,784 26,743,313 39,616,876 27,272,672 39,847,834 29,710,043 230,958 10,137,79 Liabilities + Fund Balance 154,123,537 155,232,299 149,065,629 152,265,708 149,532,205 150,939,543 145,594,746 (1,326,165) 5,344,79		31 506	147 821	36 044	127 821	68 644	127 821	107 118	_	20.703
Fund Balance 31,992,031 36,994,377 23,268,194 36,447,220 23,786,064 36,928,877 26,459,404 481,657 10,469,47 Temporarily Restricted 1,467,786 1,468,166 2,610,594 1,468,293 2,610,720 1,468,417 2,610,841 124 (1,142,42 Net Income 5,002,346 2,306,242 864,526 1,701,362 875,889 1,450,539 639,798 (250,823) 810,74 Total Fund Balance 38,462,163 40,768,784 26,743,313 39,616,876 27,272,672 39,847,834 29,710,043 230,958 10,137,79 Liabilities + Fund Balance 154,123,537 155,232,299 149,065,629 152,265,708 149,532,205 150,939,543 145,594,746 (1,326,165) 5,344,79									(1 557 122)	
Fund Balance 31,992,031 36,994,377 23,268,194 36,447,220 23,786,064 36,928,877 26,459,404 481,657 10,469,47 Temporarily Restricted 1,467,786 1,468,166 2,610,594 1,468,293 2,610,720 1,468,417 2,610,841 124 (1,142,42 Net Income 5,002,346 2,306,242 864,526 1,701,362 875,889 1,450,539 639,798 (250,823) 810,74 Total Fund Balance 38,462,163 40,768,784 26,743,313 39,616,876 27,272,672 39,847,834 29,710,043 230,958 10,137,79 Liabilities + Fund Balance 154,123,537 155,232,299 149,065,629 152,265,708 149,532,205 150,939,543 145,594,746 (1,326,165) 5,344,79		113,001,373	114,405,515	122,322,313	112,040,032	122,237,332	111,071,707	113,004,703	(1,557,122)	(4,172,774)
Temporarily Restricted 1,467,786 1,468,166 2,610,594 1,468,293 2,610,720 1,468,417 2,610,841 124 (1,142,42 Net Income 5,002,346 2,306,242 864,526 1,701,362 875,889 1,450,539 639,798 (250,823) 810,74 Total Fund Balance 38,462,163 40,768,784 26,743,313 39,616,876 27,272,672 39,847,834 29,710,043 230,958 10,137,79 Liabilities + Fund Balance 154,123,537 155,232,299 149,065,629 152,265,708 149,532,205 150,939,543 145,594,746 (1,326,165) 5,344,79		31 902 031	36 994 377	23 268 104	36 447 220	23 786 064	36 928 877	26.450.404	481 657	10 469 473
Net Income 5,002,346 2,306,242 864,526 1,701,362 875,889 1,450,539 639,798 (250,823) 810,74 Total Fund Balance 38,462,163 40,768,784 26,743,313 39,616,876 27,272,672 39,847,834 29,710,043 230,958 10,137,79 Liabilities + Fund Balance 154,123,537 155,232,299 149,065,629 152,265,708 149,532,205 150,939,543 145,594,746 (1,326,165) 5,344,79								-,, -	- ,	-,,
Total Fund Balance 38,462,163 40,768,784 26,743,313 39,616,876 27,272,672 39,847,834 29,710,043 230,958 10,137,79 Liabilities + Fund Balance 154,123,537 155,232,299 149,065,629 152,265,708 149,532,205 150,939,543 145,594,746 (1,326,165) 5,344,79										
Liabilities + Fund Balance 154,123,537 155,232,299 149,065,629 152,265,708 149,532,205 150,939,543 145,594,746 (1,326,165) 5,344,79	•									
(Decime/Gain $(90,000)$ 1,771,115 $(2,900,591)$ 400,576 $(1,320,105)$ $(3,937,458)$ 1,640,426 2,611,29	•	154,145,557							. , , ,	, ,
	(Decinie)/Gain		(90,086)	1,//1,115	(2,900,391)	400,376	(1,320,103)	(3,937,438)	1,040,420	2,011,293

Calculation method agrees to SECOND and THIRD SUPPLEMENTAL INDENTURE OF TRUST 2021 Bonds Indenture

Long-Term Debt Service Coverage Ratio Calculation

Numerator:	HOSPITAL FUND ONLY
Excess of revenues over expense	\$ 1,450,539
+ Depreciation Expense	2,141,699
+ Interest Expense	1,003,930
Less GO Property Tax revenue	815,990
Less GO Interest Expense	207,895
"Income available for debt service"	\$ 3,572,284
Income available for devi service	φ 3,372,204
Denominator:	
Maximum "Annual Debt Service"	
2021A Revenue Bonds	\$ 112,700
2021B Revenue Bonds	894,160
2009 GO Bonds (Fully Accreted Value)	
2016 GO Bonds	
Financed purchases and other loans	1,546,875
Total Maximum Annual Debt Service	\$ 2,553,735
	1,064,056
Ratio: (numerator / denominator)	3.36
Required Debt Service Coverage Ratio:	1.10
	1.10
In Compliance? (Y/N)	No
In Compliance? (Y/N)	No
	No
In Compliance? (Y/N)	No Cash on Hand HOSPITAL FUND ONLY
In Compliance? (Y/N)	No Cash on Hand HOSPITAL FUND ONLY \$ 17,167,981
In Compliance? (Y/N) Unrestricted Funds and Days Cash and Investments-current Cash and Investments-non current	No No No
In Compliance? (Y/N) Unrestricted Funds and Days Cash and Investments-current	No Cash on Hand HOSPITAL FUND ONLY \$ 17,167,981
In Compliance? (Y/N) Unrestricted Funds and Days Cash and Investments-current Cash and Investments-non current Sub-total Less - Restricted:	No No No
In Compliance? (Y/N) Unrestricted Funds and Days Cash and Investments-current Cash and Investments-non current Sub-total Less - Restricted: PRF and grants (Unearned Revenue)	No No No
In Compliance? (Y/N) Unrestricted Funds and Days Cash and Investments-current Cash and Investments-non current Sub-total Less - Restricted: PRF and grants (Unearned Revenue) Held with bond fiscal agent	No Cash on Hand HOSPITAL FUND ONLY \$ 17,167,981
In Compliance? (Y/N) Unrestricted Funds and Days Cash and Investments-current Cash and Investments-non current Sub-total Less - Restricted: PRF and grants (Unearned Revenue) Held with bond fiscal agent Building and Nursing Fund	No Cash on Hand HOSPITAL FUND ONLY \$ 17,167,981
In Compliance? (Y/N) Unrestricted Funds and Days Cash and Investments-current Cash and Investments-non current Sub-total Less - Restricted: PRF and grants (Unearned Revenue) Held with bond fiscal agent	No Cash on Hand HOSPITAL FUND ONLY \$ 17,167,981
In Compliance? (Y/N) Unrestricted Funds and Days Cash and Investments-current Cash and Investments-non current Sub-total Less - Restricted: PRF and grants (Unearned Revenue) Held with bond fiscal agent Building and Nursing Fund Total Unrestricted Funds	No Cash on Hand HOSPITAL FUND ONLY \$ 17,167,981
In Compliance? (Y/N) Unrestricted Funds and Days Cash and Investments-current Cash and Investments-non current Sub-total Less - Restricted: PRF and grants (Unearned Revenue) Held with bond fiscal agent Building and Nursing Fund Total Unrestricted Funds Total Operating Expenses	No Cash on Hand HOSPITAL FUND ONLY \$ 17,167,981
In Compliance? (Y/N) Unrestricted Funds and Days Cash and Investments-current Cash and Investments-non current Sub-total Less - Restricted: PRF and grants (Unearned Revenue) Held with bond fiscal agent Building and Nursing Fund Total Unrestricted Funds Total Operating Expenses Less Depreciation	No Cash on Hand HOSPITAL FUND ONLY \$ 17,167,981
In Compliance? (Y/N) Unrestricted Funds and Days Cash and Investments-current Cash and Investments-non current Sub-total Less - Restricted: PRF and grants (Unearned Revenue) Held with bond fiscal agent Building and Nursing Fund Total Unrestricted Funds Total Operating Expenses Less Depreciation Net Expenses	No Cash on Hand HOSPITAL FUND ONLY \$ 17,167,981
In Compliance? (Y/N) Unrestricted Funds and Days Cash and Investments-current Cash and Investments-non current Sub-total Less - Restricted: PRF and grants (Unearned Revenue) Held with bond fiscal agent Building and Nursing Fund Total Unrestricted Funds Total Operating Expenses Less Depreciation	No Cash on Hand HOSPITAL FUND ONLY \$ 17,167,981

Northern Inyo Healthcare District Statement of Cash Flows Fiscal Year 2025

CASH FLOWS FROM OPERATING ACTIVITIES	
Receipts from and on Behalf of Patients	47,444,580
Payments to Suppliers and Contractors	(28,643,583)
Payments to and on Behalf of Employees	(26,641,524)
Other Receipts and Payments, Net	4,656,477
Net Cash Provided (Used) by Operating Activities	(3,184,051)
CASH FLOWS FROM NONCAPITAL FINANCING ACTIVITIES	
Noncapital Contributions and Grants	(4,487,790)
Property Taxes Received	-
Other	1,222,661
Net Cash Provided (Used) by Noncapital Financing Activities	(3,265,129)
CASH FLOWS FROM CAPITAL AND CAPITAL RELATED	
FINANCING ACTIVITIES	
Principal Payments on Long-Term Debt	(1,106,909)
Proceeds from the Issuance of Refunding Revenue Bonds	-
Payment to Defease Revenue Bonds	-
Interest Paid	(1,003,930)
Purchase and Construction of Capital Assets	(253,729)
Payments on Lease Liability	(124,557)
Payments on Subscription Liability	(361,325)
Property Taxes Received	1,058,835
Net Cash Provided (Used) by Capital and Capital Related	
Financing Activities	(1,791,613)
CASH FLOWS FROM INVESTING ACTIVITIES	
Investment Income	240,084
Rental Income	31,825
Net Cash Provided (Used) by Investing Activities	271,909
NET CHANGE IN CASH AND CASH EQUIVALENTS	(7,968,884)
Cash and Cash Equivalents - Beginning of Year	25,136,864
CASH AND CASH EQUIVALENTS - END OF YEAR	17,167,980

Provided by: Chief Financial Officer


	Key Financial Performance Indicators	Industr Benchn	•	Nov-22	Nov-23		FYE 2024 Average	Jul-24	Aug-24	Sa	ep-24	Oct-24		Nov-24	Va	riance to Prior Month	Variance to FYE 2024 Average	Variance to Prior Year Month
Volume	Rey i mancial renormance mulcators	Delicili	IIGIK	1404-22	1404-23		Average	Jui-24	Aug-24	36	:p-24	OC1-24		1404-24		Wionth	2024 Average	WOITEN
Volume	Admits		41	79	75		71	75	75		83		58	77		9	6	2
	Deliveries	n/a		16	16		17	18	19		17		21	14		(7)	(3)	(2)
	Adjusted Patient Days	n/a		1.226	940		1,035	1,164	1,362		1.312	1.3		970		(365)	(65)	30
	Total Surgeries	,	153	129	149		146	134	168		133	1	76	129		(47)	(17)	(20)
	ER Visits		659	986	750		840	903	905		947	8	59	789		(70)	(51)	39
	RHC and Clinic Visits	n/a		4,807	4,768		4,607	4,252	4,921		4,808	4,9	07	4,515		(392)	(92)	(253)
	Diagnostic Imaging Services	n/a		1,992	1,897		2,069	2,274	2,221		2,194	2,3	44	1,880		(464)	(189)	(17)
	Rehab Services	n/a		679	614		662	719	808		887	1,1	42	903		(239)	241	289
AR & Inco																		
	Gross AR (Cerner only)	n/a		\$ 55,510,968	\$ 52,529,762		52,823,707	,,						48,660,966	-	(2,924,335)		
	AR > 90 Days	\$ 7,688	-,	\$ 24,211,484	\$ 26,596,663	-	24,488,432	,,	\$ 	\$ 34,0	041,771			21,371,712		(999,817)		
	AR % > 90 Days		15%	43.6%	50.23%		46.7%	44.5%	57.2%		58.6%	43.		43.9%		0.6%	-2.7%	-6.3%
	AR Days		43.00		87.85		85.52	89.02	92.17		86.34	7	3.2	71.77		(1.43)	(13.75)	(16.08)
	Net AR	n/a		\$ 20,904,497	\$ 20,460,545		16,938,200	21,642,722	\$ 24,802,720	\$ 19,	842,483	\$ 18,705,4		20,054,289		1,348,860		(406,256)
	Net AR % of Gross	n/a		37.7%	39.0%		31.9%	38.1%	43.0%		34.1%	36.	3%	41.2%		5.0%	9.3%	2.3%
	Gross Patient Revenue/Calendar Day	n/a		\$ 589,134	\$ 599,349	\$	619,457	\$ 617,364	\$ 683,348	\$	702,988	\$ 698,3	14 \$	582,780	\$	(115,534)	\$ (36,677) \$	(16,569)
	Net Patient Revenue/Calendar Day	n/a		\$ 289,097	\$ 276,478	\$	292,759	\$ 337,843	\$ 315,574	\$:	285,805	\$ 290,2	32 \$	301,501	\$	11,268	\$ 8,742 \$	25,023
	Net Patient Revenue/APD	n/a		\$ 7,074	\$ 8,824	\$	8,757	\$ 8,998	\$ 7,183	\$	6,537	\$ 6,7	40 \$	9,325	\$	2,585	\$ 567 \$	501
Wages																		
	Wages	n/a		\$ 2,889,378	\$ 3,126,785	\$	3,285,431	\$ 3,359,076	\$ 3,241,107	\$ 3,	372,236	\$ 3,622,0	38 \$	3,463,941	\$	(158,098)	\$ 178,510 \$	337,156
	Employed paid FTEs	n/a		390.90	350.57		353.69	366.38	366.24		391.40	369.	11	364.70		(4.41)	11.01	14.13
	Employed Average Hourly Rate	\$	38.00	\$ 43.12	\$ 52.03	\$	53.32	\$ 51.76	\$ 49.96	\$	50.26	\$ 55.	40 \$	55.41	\$	0.01	\$ 2.09 \$	3.38
	Benefits	n/a		\$ 1,803,140	\$ 1,804,521	\$	1,640,216	\$ 1,509,407	\$ 1,478,605	\$ 1,0	634,036	\$ 1,896,2	56 \$	713,356	\$	(1,182,910)	\$ (926,860) \$	(1,091,165)
	Benefits % of Wages		30%	62.4%	57.7%		50.3%	44.9%	45.6%		48.5%	52.	4%	20.6%		-31.8%	-29.7%	-37.1%
	Contract Labor	n/a		\$ 1,649,618	\$ 211,163	\$	518,351	\$ 507,387	\$ 829,876	\$ (112,642)	\$ 543,8	29 \$	583,367	\$	39,538	\$ 65,016 \$	372,204
	Contract Labor Paid FTEs	n/a		35.82	21.61		23.49	29.45	32.19		24.84	21.	32	23.57		2.24	0.07	1.96
	Total Paid FTEs	n/a		426.72	372.18		377.18	395.83	398.43		416.25	390.	44	388.27		(2.17)	11.09	16.09
	Contract Labor Average Hourly Rate	\$	81.04	\$ 268.64	\$ 57.00	\$	126.74	\$ 97.26	\$ 145.55	\$	118.60	\$ 143.	96 \$	144.39	\$	0.43	\$ 17.66 \$	87.39
	Total Salaries, Wages, & Benefits	n/a		\$ 6,342,136	\$ 5,142,469	\$	5,443,998	\$ 5,375,870	\$ 5,549,587	\$ 4,	893,631	\$ 6,062,1	33 \$	4,760,664	\$	(1,301,469)	\$ (683,334) \$	(381,805)
	SWB% of NR		50%	73.1%	62.0%		63.2%	51.3%	56.7%		57.1%	67.	4%	48.7%		-18.7%	-14.5%	-13.3%
	SWB/APD		2,607	\$ 5,173	\$ 5,471	\$	5,346	\$ 4,618	\$ 4,075	\$	3,731	\$ 4,5	41 \$	4,908	\$	367	\$ (438) \$	(563)
	SWB % of total expenses		50%	69.8%	55.4%		56.7%	59.6%	56.3%		55.1%	58.	0%	49.7%		-8.3%	-7.0%	-5.7%


Provided by: Chief Financial Officer


																						Va	riance to
							FYE 2024											Va	riance to Prior	Varia	nce to FYE	Pi	rior Year
Physician	Spend						Average		Jul-24		Aug-24	9	Sep-24		Oct-24		Nov-24		Month	2024	Average		Month
	Physician Expenses	n/a	:	\$ 1,556,109	\$ 1,713,978	\$	1,507,510	\$	1,553,004	\$	1,399,376	\$	1,621,308	\$	1,699,955	\$	1,508,531	\$	(191,424)	\$	1,020	\$	(205,447)
	Physician expenses/APD	n/a	:	\$ 1,269	\$ 1,823	\$	1,478	\$	1,334	\$	1,028	\$	1,236	\$	1,273	\$	1,555	\$	282	\$	77	\$	(268)
																		\$	-	\$	-	\$	-
Supplies																							
	Supply Expenses	n/a		\$ 1,071,178			776,504	\$	387,610		30 1,003	\$	353,623		,	\$	1,034,853		537,889		258,349		178,613
	Supply expenses/APD		:	\$ 874	\$ 911	\$	780	\$	333	\$	664	\$	270	\$	372	\$	1,067	\$	695	\$	287	\$	156
Other Ex																							
	Other Expenses	n/a	:	,	\$ 1,568,875	-	1,891,477	\$	1,696,938	\$,,-	\$	2,008,508				2,271,303		83,534		379,826		702,427
	Other Expenses/APD	n/a	:	\$ 91	\$ 1,669	\$	1,878	\$	1,458	\$	1,474	\$	1,531	\$	1,639	\$	2,342	\$	703	\$	464	\$	673
Margin		,								_		_			/	_	/·	_		_		_	
	Net Income	n/a	:	\$ (2,424,941)			383,763	\$	2,041,456	Ş	248,064	\$	19,121	\$	(1,152,036)	Ş	(250,823)	\$	901,213	Ş	(634,586)	Ş	(14,733)
	Net Profit Margin	n/a		-28.0%			3.0%		19.5%		2.5%		0.2%		-12.8%		-2.6%		10.2%		-5.5%		0.2%
	Operating Income	n/a		\$ (2,579,099)			(686,403)		1,459,716	Ş	(77,526)	\$	(302,930)	\$	(, -,,	\$	(530,332)	\$	919,284	Ş	156,071	Ş	456,900
	Operating Margin	,	2.9%	-29.7%			-10.9%		13.9%	_	-0.8%	_	-3.1%		-16.1%		-5.4%	_	10.7%	_	5.5%	_	6.5%
	EBITDA	n/a		\$ (2,770,959)			841,932		2,482,790	Ş	689,172	\$	459,316	\$	(742,505)	Ş	158,708	\$	901,213	Ş	(683,224)	Ş	38,622
	EBITDA Margin		12.7%	-31.9%			8.7%		23.7%		7.0%		4.7%		-8.3%		1.6%		9.9%		-7.1%		0.2%
	Debt Service Coverage Ratio		3.70		4.4		3.3		0.8		7.3		5.5		3.3		3.4		0.0		0.0		(1.0)
Cl-																							
Cash	Avg Daily Disbursements (excl. IGT)	n/a		\$ 382,431	\$ 379,443	4	355,328	ć	367.107	,	398,922	Ļ	315.796	Ļ	399.234	Ļ	296.503	ć	(102,732)	ć	(58,826)	۲.	(82,941)
	9 , , ,			, .					, .			ç	,		,		,		. , ,			-	
	Average Daily Cash Collections (excl. IGT)	n/a		237,301			299,110		349,783		262,199	>	302,042		359,292		288,101	-	(71,191)		(11,009)		(18,374)
	Average Daily Net Cash	,		\$ (85,130)	. , , ,		(56,218)		(17,324)		(136,723)		(13,754)		(39,942)		(8,402)	-	31,540		47,816		64,567
	Unrestricted Funds	n/a		-,,-	\$ 21,068,202		23,536,438		27,015,779	\$,,		4,708,310		22,963,678		-,,-		(6,864,309)		(7,437,069)		(4,968,833)
	Change of cash per balance sheet	n/a			\$ (5,304,581	\$	(541,459)	\$	1,876,964	\$	(2,648,999)	\$	341,530	\$	(1,744,632)	۶ (\$	(5,119,676)	\$	(6,322,850)	\$	(1,559,728)
	Days Cash on Hand (assume no more cash is collected)		196	78	56		72		98		84		58		77		43		(34)		(29)		(13)
	Estimated Days Until Depleted			277	339		406		506		413		440		442		372		(70)		(33)		33
	Years Until Cash Depletion			0.76	0.93		1.11		1.39		1.13		1.21		1.21		1.02		(0.19)		(0.09)		0.09





INCOME

































KEY PERFORMANCE INDICATORS









WAGE COSTS

	November 2022	November 2023	November 2024
Total Paid FTEs	427	372	388
Salaries, Wages, Benefits (SWB) Expense (incl. contract labor)	\$6,342,136	\$5,142469	\$4,760,664
SWB % of total expenses (including contract labor)	69.8%	55.4%	48.7%
Employed Average Hourly Rate	\$43.12	\$52.03	\$55.40
Benefits % of Wages	62.4%	57.7%	20.6%

	Final FYE 2024	YTD Nov Actual	Annualized FYE 2025	Adjustment	FYE 2025 Projection	Variance to PYTD Comment
Revenue						
Inpatient Patient Revenue Outpatient Revenue	41,350,077	18,722,057	44,932,937		44,932,937	9% Volume is consistently higher Starting to see decline in some surgeries. Also, observation hours process change in women's
Clinic Revenue	166,037,287	73,012,307	175,229,537	(3,000,000)	172,229,537	4% service line Starting to see decline in RHC (primary care) visits along with decline in ortho clinic
Cililic Reveilue	10 200 007	0 017 410	24 464 904	(E00.000)	20 661 804	7%
Cerner Unaliased	19,388,997	8,817,418 (8,930)	21,161,804	(500,000)	20,661,804 -21,432	100%
Gross Patient Service Revenue	226,776,361	100,542,853	(21,432) 241,302,847	(3,500,000)	237,802,847	5%
Deductions from Revenue	(119,667,037)	(53,127,846)	(127,506,830)	1,900,000	-125,606,830	5% adjusting to keep NR% of GR consistent
Other Revenue	6,979	4,435	10,643	1,300,000	10.643	53%
Net Patient Service Revenue	107,116,303	47,419,442	113,806,660	(1,600,000)	112,206,660	5%
	47.2%	47.2%	47.2%	45.7%	47.2%	0%
Expense	2,0	270		10.1. 70	270	
Salaries and Wages	38,674,815	17,058,398	40,940,155		40,940,155	6% Increased employee average rate Anticipated savings in MDV due to less claims
Benefits						along with lower pension expense of \$1M
	22,390,958	7,231,310	17,355,143	3,000,000	20,355,143	-9%
Contract Labor	6,024,606	2,351,817	5,644,361	380,245	6,024,606	0% Keeping flat to prior year
Professional Fees	24,725,996	10,064,237	24,154,170	571,826	24,725,996	0% Keeping flat to prior year
Pharmacy	5,832,893	1,669,046	4,005,711	1,827,182	5,832,893	0%
Medical Supplies Other Expenses	4,702,267	2,478,139	5,947,534		5,947,534	26% Increased volume Increased utilities, insurance, repairs, cerner expenses along with billing/collection fees
outer Expenses	10,856,091	4,781,663	11,475,991	1,000,000	12,475,991	15%
Depreciation and Amortization	5,163,844	2,141,699	5,140,079	1,000,000	5.140.079	0%
Total Expenses	118,371,469	47,776,309	114,663,143	6,779,253	121,442,396	3%
Financing Expense	2,962,395	1,003,930	2,409,432		2,409,432	-19% Less interest expense on debt
Financing Income	3,155,532	1,222,661	2,934,387		2,934,387	-7%
Investment Income	724,763	240,084	576,202		576,202	-20% Investing less cash due to constraints
Total Grant Revenue						
Miscellaneous Income	12,319,227	1,347,654	3,234,369	9,084,858	12,319,227	0% IGT - keeping consistent with prior year
Net Income/(Loss)	1,981,960	1,449,601	3,479,044	705,605	4,184,648	111%

NIHD FYE 2025 Cash Projection

		NIHD FYE 2025 Cash	Projection
		FYE 2025	Comment
YTD Cash Collections (Dec 2024)	\$	58,181,021	\$2M higher than December 2023 YTD
One time items:			
Grants		103,312	
IGT		1,139,051	
Tax Appropriations		163,826	
Other		479,570	-
Total non-recurring cash	\$	1,885,758	
Francisco de la constitución de			
Expected one-time items:	۲	102 212	Using first 6 months as basis
Grants	Ş	103,312	Using first 6 months as basis 2 more quarterly HQAF, annual HQAF, AB 915, rate range,
IGT	¢	11 000 000	and QIP - should be recouped by June
Tax Appropriations			Based on prior year
ERC		2,000,000	IRS Tax credit - IRS is slow to processing ~\$5M
Other		250 000	CDs maturing by June
Total expected one-time items		13,353,312	_ CD3 mataring by June
Total expected one time terms	7	13,333,312	
Projected FYE 2025 cash intake	\$	125,943,838.20	Prior year was \$127.4M
YTD Disbursements	\$	/72 070 200\	
One time items:	<u> </u>	(72,079,209)	-
Bond payments	¢	(1,967,350)	
SB1334 Retro			Missed rest breaks paid in August
Capital			Q1 approved budget
IGT		(4,518,915)	- · · · · · · · · · · · · · · · · · · ·
Total non-recurring disbursements	\$	(9,538,555)	
	,	(=,===,===,	
Expected one-time items:			
Bond payments	\$	(376,625)	
Capital	\$	(1,500,000)	Q2 - Q4 approved budget
Total expected one-time items	\$	(1,876,625)	
Projected FYE 2025 disbursements	\$	(126,957,933)	Prior year was \$132.3M
Projected 2025 Net Cash	\$	(1,014,095)	
Daily Deficit	\$	(2,771)	
bully beliefe	•	(=,,,,=,	
Available Balances at 2	12/31		_
ESBC General Checking		6,347,025	
US Bank Checking US Bank RHC		951,030 246,308	
US Bank Athena		898,975	
LAIF		5,281,865	
CDs maturing within 3 months		1,000,000	
Cash or cash equivalents	\$	14,725,203	
CD - not available as cash equivalent	\$	1,000,000	_
Total with investments	\$	15,725,202.70	
June 2024 cash balances	\$	18,718,414	
December 2024 cash balances	\$	14,725,203	_
Depletion	\$	(3,993,211)	
Average Depletion per month	\$	(665,535)	Using projected daily deficit
Average Daily Depletion		(22,185)	\$ (2,771)
Days until depleted		663.76	5,314.52
Years until depleted		1.8	14.56
Estimated Ending Cash Balances	\$	14,218,155	
Days cash on hand		43	



DATE: January 2025

TO: Board of Directors, Northern Inyo Healthcare District

FROM: Andrea Mossman CFO

RE: JORIE

The Goal of AI Adoption: Efficiency, Not Replacement

I want to be clear: this adoption of AI technology is designed to *add efficiencies* to our workflow, not to replace any of our valuable team members. As the saying goes, we're here to "work smarter, not harder." By automating some of the daily tasks, Jorie AI will allow you to focus on the more complex aspects of your work—such as problem-solving and providing exceptional service to our patients. The AI can certainly assist, but no AI solution is flawless. It will always require human oversight to ensure its accuracy.

Here are a couple of examples where AI is helping humans work more efficiently:

- ChatGPT: A powerful tool that can rewrite documents and emails, making them more concise and professional. While it makes the process easier, it still requires human input to create the content.
- **Zoom AI Summary**: This tool summarizes meetings and creates actionable to-do lists from virtual meetings. It cuts down on the time spent taking notes, so you can focus on engaging in discussions. While I still review and edit the summaries, it has saved me a significant amount of time and ensures nothing gets missed.

Why Jorie AI?

You might be wondering, "Why are we adding Jorie AI to the mix?" Our revenue cycle has certainly improved over the past two years, but we're still not where we need to be compared to industry standards. We're facing slower billing times, weak cash collections, and higher insurance denials compared to our peers. Insurance companies are leveraging AI to make decisions on denials, which makes it more difficult for us to contest these claims effectively. Our external billing team was also struggling to meet productivity and performance standards, which impacts the long-term sustainability of our district.

Jorie AI will automate many back-office billing processes, starting with Medicare and commercial payers. As a result, we've notified OS Healthcare that their contract will end on 2/1/25. Jorie will be focused on handling these areas first, and we'll reassess other external billing relationships as needed.

Impact on Your Work

I know many of you have questions about how this change will affect your day-to-day responsibilities. The truth is, we don't have all the answers yet. While we've seen demonstrations of Jorie AI, it's not fully integrated into our revenue cycle system yet. We're still in the discovery phase, working on the standard operating procedures (SOPs) for the project. So, until the system is live in production, we can't say with certainty how it will work in practice.

What I can say is that this AI isn't intended to replace anyone on the team. We're looking for ways to support you in improving efficiency and achieving a more manageable workload. Many of you have been juggling increasing responsibilities due to staffing challenges and growing volumes, and we hope that the addition of AI will alleviate some of that pressure. But rest assured, AI won't handle everything perfectly. It will still need human oversight for all areas of the revenue cycle.

The Path Forward

When will this project be completed? Our first priority is implementing AI in the Medicare and commercial billing processes by 2/1/25, as our current external billing provider's contract ends. But this is just the beginning. We expect this project to extend throughout much of 2025 as we evaluate what Jorie AI is capable of and what areas could benefit from further automation. We will continue to monitor and assess its performance, always focusing on ensuring it adds value to our team and our organization.

Looking Ahead: What Other Changes Are Coming?

Our leadership team is always working to stay ahead of the latest trends in healthcare, and while we're not currently reviewing other AI technologies, we're committed to being proactive and forward-thinking. As a district, we'll also be focusing on collecting upfront cash for elective services, which is the industry standard. We're striving to improve our financial sustainability, ensuring we can continue to serve our patients for years to come.

CALL TO ORDER Northern Inyo Healthcare District (NIHD) Board Chair Melissa Best-Baker

called the meeting to order at 5:00 pm.

PRESENT Melissa Best-Baker, Chair

Jean Turner, Vice Chair

David McCoy Barrett, Treasurer

Mary Mae Kilpatrick, Member at Large Laura Smith, New Board Member David Lent, New Board Member

Stephen DelRossi, Chief Executive Officer

Allison Partridge, Chief Operations Officer / Chief Nursing Officer

Adam Hawkins, DO, Chief Medical Officer

Alison Murray, Chief Human Resources Officer, Chief Business Development

Officer

Andrea Mossman, Chief Financial Officer

Sierra Bourne, MD, Chief of Staff

PUBLIC COMMENT Chair Best-Baker reported that, at this time, audience members may speak on

any items not on the agenda that are within the board's jurisdiction.

There were no comments from the public.

CEO THANK YOU CEO DelRossi thanked Mary Mae Kilpatrick for her service on the Board of

Directors.

OATH OF OFFICE David Lent, David McCoy Barrett, and Laura Smith took the oath of office and

were welcomed as returning and new board members.

PUBLIC COMMENT ON

CLOSED SESSION ITEMS

There were no public comments.

ADJOURNMENT TO

CLOSED SESSION

CLOSED SESSION

Adjournment to closed session at 05:06 pm

RETURN TO OPEN

SESSION

Called back to order at 06:32 pm

Chair Best-Baker stated there were no reportable actions from the closed

session.

SLATE OF OFFICERS Chair: Jean Turner

Vice-Chair: Melissa Best-Baker

Secretary: David Lent

Treasurer: David McCoy Barrett Member at Large: Laura Smith

Motion to approve the slate of officers: Barrett

2nd: Lent Passed

NEW BUSINESS

SEMINAR 2025

Chair Best-Baker called attention to the Board of Directors Seminar 2025

CEO DelRossi explained that the Board of Directors will have a seminar in January 2025.

Operation Manual – will be delivered to the Board of Directors before the seminar.

CHIEF EXECUTIVE OFFICER REPORT

Chair Best-Baker called attention to the CEO report.

Strategic Plan – the strategic plan was created with collaboration between the Executive Team and the Board of Directors.

Motion to approve the strategic plan: Smith 2nd: Barrett

Passed

Ophthalmology—CEO DelRossi referred to the letter in the packet and commented that NIHD is committed to finding programs that are sustainable for the hospital.

CHIEF FINANCIAL OFFICER REPORT

Chair Best-Baker introduced the Chief Financial Officer's Report.

Financial and Statistical reports discussion ensued.

- 1. Barrett expressed his ongoing concern about high AR days. People have been reporting that they are accessing healthcare and do not receive bills timely.
- 2. DelRossi responded:
 - a. Jorie will be implemented in February 2025. Jorie will help with the coordination of benefits and will verify the correct insurance allowing the billing to take place timely with fewer mistakes.
 - b. Starting in January 2025, co-payments and the patient portion of procedures will be collected at the time of the visit/procedure.

Motion to accept financial and statistical reports: Turner

2nd: Barrett Passed

CHIEF MEDICAL OFFICER REPORT

No Report out

CHIEF OF STAFF REPORT

Chair Best-Baker called attention to the Chief of Staff Report.

Medical Staff Appointments 2024-2025

Motion to approve medical staff appointments: Smith

2nd: Turner Passed

Medical Staff Appointments 2024-2025 – Proxy Credentialing Motion to approve medical staff appointments: Turner 2nd: Smith Passed

Medical Staff Reappointments 2025-2026 Motion to approve the medical staff reappointments: Barrett 2nd: Turner Passed

Medical Executive Committee Report Dr. Bourne expressed gratitude to staff and physicians for their compassionate care for patients and their families during a recent visit.

CONSENT AGENDA

Removed from the consent agenda:

- 1. NIHD Recruitment and Selection Education and Experience Equivalency
- 2. Approval of minutes of the November 20, 2024 Regular Board Meeting

Motion to approve remaining items on the consent agenda: Turner 2nd: Barrett
Passed

- 3. Approval of minutes of the November 20, 2024 Regular Board Meeting a. Corrected "Northern Invo Healthcare District (NIHD) Board
 - a. Corrected "Northern Inyo Healthcare District (NIHD) Board Vice-Chair Turner called the meeting to order at 5:00 pm."

Motion to approve meeting minutes with correction: Barrett 2nd: Turner
Passed

Public Comment: Rosie Graves – expressed concern over the NIHD Recruitment and Selection – Education and Experience Equivalency Policy.

- 1. Graves expressed frustration over equating one year of work experience to one year of education.
- 2. Graves urged the district to create a 2-tier pay scale for managers with and without college degrees.
- 3. Graves expressed a belief that education can increase a company's foundation, and challenge aspiring managers to grow.

The board expressed an understanding of the difficulty of recruiting in rural areas, the value of education, and the need to balance work experience and education.

NIHD will review this policy.

Northern Inyo Healthcar	e District Board of Directors
Regular Meeting	

December 11, 2024 Page 4 of 4

GENERAL INFORMATION FROM BOARD MEMBERS					
	Kilpatrick enjoyed participating in the Main Street Parade with other NIHD staff.				
ADJOURNMENT	Adjournment at 8:06 pm.				
	Jean Turner				
	Northern Inyo Healthcare District Chair				
	Attest:				
	David Lent Northern Inyo Healthcare District Chair Secretary				



December 2024 Statement

Open Date: 11/06/2024 Closing Date: 12/04/2024

U.S. Bank Business Platinum Card

NORTHERN INYO HOSPITA

STEPHEN DELROSSI

New Balance	\$4,401.91
Minimum Payment Due	\$45.00
<u> </u>	01/01/2025

Cardmember Service

Page 1 of 3

Activity Summary		
Previous Balance	+	\$11,232.68
Payments	-	\$11,232.68cR
Other Credits		\$0.00
Purchases	+	\$4,401.91
Balance Transfers		\$0.00
Advances		\$0.00
Other Debits		\$0.00
Fees Charged		\$0.00
Interest Charged		\$0.00
New Balance	=	\$4,401.91
Past Due		\$0.00
Minimum Payment Due		\$45.00
Credit Line		\$37,500.00
Available Credit		\$33,098.09
Days in Billing Period		29

Please detach and send coupon with check payable to: U.S. Bank



24-Hour Cardmember Service:

to pay by phone to change your a

. to change your address

Account Number Payment Due Date 1/01/2025 **New Balance** \$4,401.91 \$45.00 **Minimum Payment Due**

Amount Enclosed

What To Do If You Think You Find A Mistake On Your Statement

If you think there is an error on your statement, please call us at the telephone number on the front of this statement, or write to us at: Cardmember Service,

In your letter or call, give us the following information:

• Account information: Your name and account number.

- Dollar amount: The dollar amount of the suspected error.
- Description of Problem: If you think there is an error on your bill, describe what you believe is wrong and why you believe it is a mistake. You must contact us within 60 days after the error appeared on your statement. While we investigate whether or not there has been an error, the following are true:
- ▶ We cannot try to collect the amount in question, or report you as delinquent on that amount.
- The charge in question may remain on your statement, and we may continue to charge you interest on that amount. But, if we determine that we made a mistake, you will not have to pay the amount in question or any interest or other fees related to that amount.
- While you do not have to pay the amount in question, you are responsible for the remainder of your balance.

▶ We can apply any unpaid amount against your credit limit. Your Rights If You Are Dissatisfied With Your Credit Card Purchases

If you are dissatisfied with the goods or services that you have purchased with your credit card, and you have tried in good faith to correct the problem with the merchant, you may have the right not to pay the remaining amount due on the purchase. To use this right, all of the following must be true:

- 1. The purchase must have been made in your home state or within 100 miles of your current mailing address, and the purchase price must have been more than \$50. (Note: Neither of these are necessary if your purchase was based on an advertisement we mailed to you, or if we own the company that sold you the goods or services.)
- 2. You must have used your credit card for the purchase, Purchases made with cash advances from an ATM or with a check that accesses your credit card account do not qualify.
 3. You must not yet have fully paid for the purchase.
- If all of the criteria above are met and you are still dissatisfied with the purchase, contact us in writing at: Cardmember Service.

While we investigate, the same rules apply to the disputed amount as discussed above. After we finish our investigation, we will tell you our decision. At that point, if we think you owe an amount and you do not pay we may report you as delinquent. Important Information Regarding Your Account

- Information Regarding Total Account
 I, INTEREST CHARGE: Method of Computing Balance Subject to Interest Rate: We calculate the periodic rate or interest portion of the
 INTEREST CHARGE by multiplying the applicable Daily Periodic Rate ("DPR") by the Average Daily Balance ("ADB") (including new
 transactions) of the Purchase, Advance and Balance Transfer categories subject to interest, and then adding together the resulting interest
 from each category. We determine the ADB separately for the Purchases, Advances and Balance Transfer categories. To get the ADB in each category, we add together the daily balances in those categories for the billing cycle and divide the result by the number of days in the billing cycle. We determine the daily balances each day by taking the beginning balance of those Account categories (including any billed but unpaid interest, fees, credit insurance and other charges), adding any new interest, fees, and charges, and subtracting any payments or credits applied against your Account balances that day. We add a Purchase, Advance or Balance Transfer to the appropriate balances for those categories on the later of the transaction date or the first day of the statement period. Billed but unpaid interest on Purchases, Advances and Balance Transfers is added to the appropriate balances for those categories each month on the statement date. Billed but unpaid Advance Transaction Fees are added to the Advance balance of your Account on the date they are charged to your Account. Any billed but unpaid fees on Purchases, credit insurance charges, and other charges are added to the Purchase balance of the Account on the date they are charged to the Account, Billed but unpaid fees on Balance Transfers are added to the Balance Transfer balance of the Account on the date they are charged to the Account. In other words, billed and unpaid interest, fees, and charges will be included in the ADB of your Account that accrues interest and will reduce the amount of credit available to you. To the extent credit insurance charges, overlimit fees, Annual Fees, and/or Travel Membership Fees may be applied to your Account, such charges and/or fees are not included in the ADB calculation for Purchases until the first day of the billing cycle following the date the credit insurance charges, overlimit fees, Annual Fees and/or Travel Membership Fees (as applicable) are charged to the Account. Prior statement balances subject to an interest-free period that have been paid on or before the payment due date in the ADB calculation.
- 2. Payment Information: We will accept payment via check, money order, the internet (including mobile and online) or phone or previously established automatic payment transaction. You must pay us in U.S. Dollars. If you make a payment from a foreign financial institution, you will be charged and agree to pay any collection fees added in connection with that transaction. The date you mail a payment is different than the date we receive the payment. The payment date is the day we receive your check or money order at U.S. Bank National Association, for the day we receive your internet or phone payment. All payments by check or money order accompanied by a payment coupon and received at this payment address will be credited to your Account on the day of receipt if received by 5:00 p.m. CT on any banking day. Payments sent without the payment coupon or to an incorrect address will be processed and credited to your Account within 5 banking days of receipt. Payments sent without a payment coupon or to an incorrect address may result in a delayed credit to your Account, additional interest charges, fees, and/or Account suspension. The deadline for on-time internet and phone payments varies, but generally must be made before 5:00 p.m. CT to 8 p.m. CT depending on what day and how the payment is made. Please contact Cardmember Service for internet, phone, and mobile crediting times specific to your Account and your payment option. Banking days are all calendar days except Saturday, Sunday and federal holidays. Payments due on a Saturday, Sunday or federal holiday and received on those days will be credited on the day of receipt. There is no prepayment penalty if you pay your balance at any time prior to your payment due date.
- 3. Credit Reporting: We may report information on your Account to Credit Bureaus, Late payments, missed payments or other defaults on your Account may be reflected in your credit report.



December 2024 Statement 11/06/2024 - 12/04/2024

Page 2 of 3

NORTHERN INYO HOSPITA STEPHEN DELROSSI

Signature/Approval:

Cardmember Service



Important Messages

Paying Interest: You have a 24 to 30 day interest-free period for Purchases provided you have paid your previous balance in full by the Payment Due Date shown on your monthly Account statement. In order to avoid additional INTEREST CHARGES on Purchases, you must pay your new balance in full by the Payment Due Date shown on the front of your monthly Account statement.

There is no interest-free period for transactions that post to the Account as Advances or Balance Transfers except as provided in any Offer Materials. Those transactions are subject to interest from the date they post to the Account until the date they are paid in full.

Skip the mailbox. Switch to e-statements and securely access your statements online. Get started at usbank.com/lcgin.

		iu Otile	r Credits			
Post Date	Trans Date	Ref#	Transaction Description		Amount	Notatio
11/25	11/25	0000	INTERNET PAYMENT THANK YOU		\$11,232,68CR	
				TAL THIS PERIOD	\$11,232.68CR	
Purch	ases a	nd Oth	er Debits		-	
Post Date	Trans Date	Ref #	Transaction Description		Amount	Notatio
11/12	11/10		CMT CHICAGO IL27690015 CHICAGO	IL	\$55.50	CEO Cor
11/12	11/10		UNITED HOUSTON	TX	\$40.00	CEO Cor
11/15	11/13		UNITED	TX	\$40.00	CEO Cor
11/18	11/14		HYATT REGENCY CHICAGO CHICAGO FOR 04 NIGHTS	O IL	\$1,714.15	CEO Cor
11/18	11/14		TAPENADA T1 ORD CHICAGO	L	\$28.82	CEO Cor
11/18	11/17		VISTAPRINT		\$110.90	Holiday
11/21	11/20		SHARPSHEETS		\$198.00	Report T
11/21	11/20		TST* WHISKEY CREEK BISHOP	CA	\$50.00	Board Lu
12/02	11/30		FACEBK *LPFDNE4LU2		\$85.14	Marketir Holiday
12/03	12/02		TOTALLY CHO		\$2,079.40	Tionday
			то	TAL THIS PERIOD	\$4,401.91	
			2024 Totals Year-to	-Date		
			Total Fees Charged in 2024 Total Interest Charged in 2024	\$78.00 \$255.74		

Accounting Code:



December 2024 Statement 11/06/2024 - 12/04/2024

NORTHERN INYO HOSPITA STEPHEN DELROSSI

Cardmember Service

Page 3 of 3

Interest Charge Calculation

Your Annual Percentage Rate (APR) is the annual interest rate on your account.

^{**}APR for current and future transactions.

Balance Type	Balance By Type	Balance Subject to Interest Rate	Variable	Interest Charge	Annual Percentage Rate	Expires with Statement
**BALANCE TRANSFER	\$0.00	\$0.00	YES	\$0.00	23.49%	
**PURCHASES	\$4,401.91	\$0.00	YES	\$0.00	23.49%	
**ADVANCES	\$0.00	\$0.00	YES	\$0.00	29.99%	



NORTHERN INYO HOSPITA

Time to update your email? Check your usbank.com profile

Dont miss out on exclusive offers and important updates. Simply provide your current email address and opt into marketing, then enjoy all the benefits of your U.S. Bank account.

You may change your email marketing preferences at any time in the Privacy section of usbank.com. Note that confidential, personal or financial information will never be sent or requested in an email from U.S. Bank.

NORTHERN INYO HEALTHCARE DISTRICT



PLAN

Title: ALARA Program				
Owner: Manager of Diagnostic Im-	aging Services	Department: Diagnostic Imaging		
Scope: Diagnostic Imaging, Hospital Clinical Staff				
Date Last Modified: 12/07/2022 Last Review Da		e: 12/04/2024	Version: 3	
Final Approval by: NIHD Board of Directors		Original Appro	val Date: 06/20/2017	

PURPOSE:

The purpose of establishing an ALARA (as low as reasonably achievable) Program is to incorporate practices, procedures and quality assurance checks to keep occupational and medical exposure to radiation as low as reasonably achievable.

Definitions:

ALARA – "as low as reasonably achievable," acronym for the philosophy of keeping medical and occupational radiation exposure as low as reasonable achievable.

RSO - Radiation Safety Officer

RSC – Radiation Safety Committee

POLICY:

The term ALARA is an acronym for maintaining radiation exposures, and effluent releases of radioactive material in uncontrolled areas "as low as reasonably achievable" taking into account the available technology, economic costs in relation to benefits to the public health and safety, and other societal and socioeconomic considerations in their relationship with the utilization of radioactive materials and radiation – producing equipment in the public interest.

The ALARA philosophy extends to exposure to individuals in the performance of their duties (Occupational exposure) and to patients undergoing medical evaluations and treatments.

To achieve this goal, the management should address dose reduction for both workers and patients.

Although the program presented here is developed specifically for occupational exposure considerations, management should incorporate into their program those procedures, practices, and quality assurance checks that can eliminate unnecessary or extraneous radiation exposures to patients without compromising the quality of medical service. Such practices and checks include, but are not limited to:

- a) Use of appropriate and well-calibrated instrumentation and equipment.
- b) Use of appropriate digital imaging techniques
- c) Staying with the well-established dosage limits unless deviation is absolutely essential in the judgment of the responsible physician.

1. Management Commitment

- a) We, the management of Northern Inyo Healthcare District, are committed to an efficient medical use of radioactive materials and radiation producing equipment by limiting their use to clinically indicated procedures, utilizing efficient exposure techniques, and optimally operated radiation equipment; limiting dosages to those recommended by the manufacturer unless otherwise necessary, using calibrated diagnostic and related instrumentation; and using appropriately trained personnel.
- b) We commit to the program described below for keeping occupational individual and collective doses ALARA. Toward this commitment, we hereby describe an administrative organization for radiation safety and will develop all necessary written policy, procedures, and instruction to foster the ALARA philosophy within our institution. The organization will include a Radiation Safety Committee (RSC) and a Radiation Safety Officer (RSO).
- c) We will perform a formal annual review of the radiation safety program, including ALARA considerations. The review will cover operating procedures and past dose records, inspections, and recommendations of the radiation safety staff or consultants.
- d) We will modify operating and maintenance procedures, equipment, and facilities if these modifications will reduce exposures and the cost is justified.

2. Radiation Safety Committee

- a) Review of Proposed Users and Uses
 - (1) The RSC will thoroughly review the qualifications of each applicant with respect to the types and quantities of radioactive materials and radiation-producing equipment and methods of use for which application has been made, to ensure that the applicant will be able to take appropriate measures to maintain exposure ALARA.
 - (2) When considering a new use of radioactive material or radiation producing equipment, the RSC will review the efforts of the applicant to maintain exposure ALARA.
 - (3) The RSC will ensure that the users justify their procedures and that individual and collective doses will be ALARA.
- b) Delegation of Authority

(The judicious delegation of RSC authority is essential to the enforcement of an ALARA program.)

- (1) The RSC will delegate authority to the RSO for enforcement of the ALARA program.
- (2) The RSC will support the RSO when it is necessary for the RSO to assert authority. If the RSC has overruled the RSO, it will record the basis for its action in the minutes of the quarterly meeting.
- c) Review of ALARA Program
 - (1) The RSC will encourage all users to review current procedures and develop new procedures as appropriate to implement the ALARA concept.
 - (2) The RSC will perform an annual review of occupational radiation exposure. A special meeting may be called for particular attention to instances in which the investigational levels in Table 1 are exceeded. The principal purpose of this review is to assess trends in occupational exposure as an index of the ALARA program quality and to decide if action is warranted when investigational levels are exceeded (see Section 4 below for a discussion of investigational levels). Maximum legal limits of occupational exposure are listed in Table 2, for reference.

(3) The RSC will evaluate the institution's overall efforts for maintaining doses ALARA on an annual basis. This review will include the efforts of the RSO, authorized users, and workers as well as those of management.

Table 1
Investigational Levels*

	Investigational Levels		
	(mRem/calendar quarter)		
	Level I**	Level II**	
1. Whole body; head and trunk; active			
blood-forming organs; or gonads, lens of eye	312	624	
2. Lens of Eye	936	1872	
3. Extremities	3125	6250	
4. Skin of whole body	750	2250	
5. Thyroid uptake	0.1 uCi	0.3 uCi	

^{*}Note that investigational levels in this program are not new dose limits but serve as checkpoints above which the results are considered sufficiently important to justify investigations. See Section 4 for further discussion.

Table 2

Maximum Annual Levels*

	Maximum Annual Occupational Dose limits in mRem
1. Whole body	5,000
2. Extremities, Skin	50,000
3. Lens of the eyes	15,000
4. Fetus	500

^{*}Legal limits for occupational radiation exposure, NCRP Report No. 116, Table 19.1

^{**}Investigational levels are as listed on Radiation Detection Company Dosimetry Report.

3. Radiation Safety Officer

- a) Annual and Quarterly Review
 - (1) Annual review of the radiation safety program. The RSO will perform an annual review of the radiation safety program for adherence to ALARA concepts. Reviews of specific methods of use may be conducted on a more frequent basis.
 - (2) Quarterly review of occupational exposures. The RSO will review at least quarterly the radiation doses of authorized users and workers to determine that their doses are ALARA in accordance with the provisions of Section 5 of this program and will prepare a summary report for the RSC.
 - (3) Quarterly review of records of radiation surveys. The RSO will review radiation surveys in unrestricted and restricted areas to determine that dose rates and amounts of contamination were at ALARA levels during the previous quarter and will prepare a summary report for the RSC.
- b) Education Responsibilities for ALARA Program

The RSO (in cooperation with authorized user) will ensure that radiation workers and, as applicable,

- (1) Ancillary personnel are trained and educated in good health physics practices and procedures.
- (2) The RSO (or designee) will schedule briefings and educational sessions to inform workers of the ALARA program efforts.
- (3) The RSO (or designee) will ensure that authorized users, workers, and ancillary personnel who may be exposed to radiation will be instructed in the ALARA philosophy and informed that management, the RSC, and the RSO are committed to implementing the ALARA concept.
- c) Cooperative Efforts for Development of ALARA Procedures
 - (1) Radiation workers will be given opportunities to participate in formulating the procedures that they will be required to follow.
 - (2) Radiation workers will be instructed in recourses that may be taken if they feel that ALARA is not being promoted in the workplace.
- d) Reviewing Instances of Deviation from Good ALARA Practices
 - (1) The RSO will investigate all know instances of deviation from good ALARA practices and, if possible, will determine the causes. When the cause is known, the RSO will implement changes in the program to maintain doses ALARA.

4. Authorized Users

- a) New Methods of Use Involving Potential Radiation Doses
 - (1) The authorized user will consult with the RSO and/or RSC during the planning stage before using radioactive materials and radiation-producing equipment to ensure that doses will be kept ALARA. Simulated trials runs may be helpful.
 - (2) The authorized user will review each planned use of radioactive materials or radiation-producing equipment to ensure that doses will be kept ALARA. Simulated trial runs may be helpful.

5. Establishment of Investigational Levels in Order to Monitor Individual Occupational Radiation Doses (External and Internal)

This institution hereby establishes investigational levels for occupational radiation doses which, when exceeded, will initiate review or investigation by the RSC and/or the RSO. The investigational levels that we have adopted are listed in Table 1. These levels apply to the exposure of individual workers. The following actions will be taken at the investigational levels stated in Table 1.

- a) Personnel Dose Less than Investigational Level I
 - (1) Except when deemed appropriate by the RSO, no further action will be taken in those cases where an individual's dose is less than Table I values for the investigational Level I.
- b) Personnel Dose Equal To or Greater Than Investigational Level I But Less Than Investigational Level II
 - (1) The RSO will review the dose of each individual whose quarterly dose exceeds the investigational Level I and will report the results of the reviews at the first RSC meeting following the quarter when the dose was recorded. If the dose does not equal or exceed Investigational Level II, no specific action related to the exposure is required unless deemed appropriate by the Committee. The committee will, however, review each such dose in comparison with those of others performing similar tasks as an index of ALARA program quality and will record the review in the committee minutes.
- c) Personnel Dose Equal to and Greater Than Investigational Level II
 - (1) The RSO will investigate in a timely manner the causes of all personnel doses equaling or exceeding Investigational Level II and, if warranted, will take action. A notification letter will be sent to all personnel with doses equaling or exceeding Investigational Level II. A report of the investigation and any actions taken will be presented to the RSC at its first meeting following completion of the investigation. The details of these reports will be included in the RSC minutes.
- d) Reestablishment of Investigational Levels to Level Above Those Listed in Table 1
 - (1) In cases where a worker's or a group of workers' doses need to exceed an investigational level, a new, higher investigational level may be established for that individual or group on the basis that it is consistent with good ALARA practices. Justification for new investigational levels will be documented.
 - (2) The RSC will review the justification for and must approve or disapprove all revisions of investigational levels.

REFERENCES:

- 1. CA Title 17
- 2. CA-RHB "Guide for the preparation of an application for a radioactive materials license authorizing medical use"
- 3. 10 CFR 35, 10 CFR 20
- 4. NCRP Report No. 116, Table 19.1
- 5. Radiation Detection Company Dosimetry Report

RECORD RETENTION AND DESTRUCTION:

- Dosimetry reports will be kept for duration of employment + 30 years
- Patient dose records will be maintained in interpretive report as part of the medical record

CROSS REFERENCE P&P:

- 1. Dosimetry Program Occupational Radiation Exposure Monitoring Program
- 2. CHA records retention recommendations

Supersedes: v.2 ALARA Program*



NORTHERN INYO HEALTHCARE DISTRICT NON-CLINICAL POLICY AND PROCEDURE

Title: Diagnostic Imaging - Handling of Radioactive Packages, Non-nuclear medicine personnel					
Owner: Manager of Diagnostic Imaging Services Department: Diagnostic Imaging					
Scope: Purchasing, Security, and Nuclear Medicine					
Date Last Modified: 11/19/2021 Last Review Date: 12/04/2024 Version: 3					
Final Approval by: NIHD Board of	Directors	Original Approva	l Date: 2014		

PURPOSE: provide guidelines and documentation of training of non-nuclear medicine personnel for the safe handling and delivery (to nuclear medicine department) of radioactive packages.

POLICY:

All non-nuclear medicine personnel, i.e., security officer on duty or purchasing/materials management personnel, who may receive and/or deliver (to nuclear medicine) packages containing radioactive materials will be trained regarding proper handling and delivery of these packages.

PROCEDURE:

2. 10 CFR 35

Appropriate personnel are instructed to follow the guidelines listed below upon receiving radioactive packages. A signed copy of this procedure will be kept in the Radiology Manager's office to document training.

- □ Visually inspect the package, prior to handling. Notify Nuclear Medicine personnel immediately if package appears to be damaged or leaking. Do not handle a damaged or leaking package.
- □ Wear gloves when handling any radioactive package.
- Use cart or "dolly" to deliver radioactive packages. This maximizes distance between personnel and the package, minimizing radiation exposure rates.
- □ Promptly deliver all radioactive packages received to the Nuclear Medicine Department. If a nuclear medicine technologist is present, deliver package to them. If no nuclear medicine technologist is present, leave package at the hot lab door.
- Remove gloves immediately after delivery of package, dispose of the gloves in the Nuclear Medicine Imaging room trash.

If there are any questions regarding handling of radioactive packages, contact the Nuclear Medicine Department, ext. 2636; or the Director of Diagnostic Services at ext. 2002.

This document may be printed and used for documentation of annual training.
Trainee signature:
Nuclear Medicine Technologist – Trainer:
REFERENCES:
1 10 CFR 20

This document may be printed and used for documentation of annual training

3. Guide for the Preparation of an Application for a Radioactive Materials License Authorizing Medical Use, Retrieved from: http://www.cdph.ca.gov/pubsforms/Guidelines/Documents/RHB-MedicalGuide.pdf,

RECORD RETENTION AND DESTRUCTION: Training documentation to be kept 6 years after date of training

CROSS REFERENCED POLICIES AND PROCEDURES:

- DI NM radioactive package receipt
- DI NM General Rules for the Safe Use of Radioactive materials
- Diagnostic Imaging Radioactive Material Hot Lab Security

Supersedes: v.2 Diagnostic Imaging - Handling of Radioactive Packages, Non-nuclear medicine personnel

Northern Inyo Healthcare District One Team. One Goal. Your Health.

NORTHERN INYO HEALTHCARE DISTRICT CLINICAL POLICY

Title: Diagnostic Imaging - Imaging Equipment Quality Control				
Owner: Manager of Diagnostic	Imaging	Department: D	iagnostic Imaging	
Services				
Scope:				
Date Last Modified: Last Review Date: Version: 2				
12/06/2022 12/04/2024				
Final Approval by: NIHD Board of Directors Original Approval Date:				

PURPOSE:

Ensures Imaging Services equipment is operating in a manner that is safe and compliant with state and federal regulations

POLICY:

- 1. The imaging department technologist shall perform quality control on all imaging equipment following manufacturer recommendations located in equipment manuals.
- 2. Quality control limits are set by manufacturer, manufacturer's field service engineer (FSE), or the medical physicist.
- 3. Equipment not performing within the designated specifications shall be removed from service immediately.
- 4. The Director of Diagnostic Services (DDS) and radiologist shall be notified of deficiency or malfunction.
- 5. The DDS or designee shall contact the appropriate manufacturer or FSE, or biomedical engineer.
- 6. Following correction or repair, appropriate quality control shall be repeated.
- 7. After passing quality control standards, equipment shall be placed back into service.

REFERENCES:

- National Council on radiation protection and measurements (NCRP) Report No. 99
- California Code of Regulations Title 17

RECORD RETENTION AND DESTRUCTION:

• Until next Inspection + 6years

CROSS REFERENCED POLICIES AND PROCEDURES:

- DI Monitoring and Documentation of Fluoroscopic Quality Control
- Mammography Quality Control

Supersedes: v.1 Diagnostic Imaging - Imaging Equipment Quality Control*

Northern Inyo Healthcare District One Team. One Goal. Your Health.

NORTHERN INYO HEALTHCARE DISTRICT CLINICAL POLICY

Title: Diagnostic Imaging - Patient Priority				
Owner: Manager of Diagnostic	Imaging	Department: D	iagnostic Imaging	
Services				
Scope: Diagnostic Imaging Department				
Date Last Modified: Last Review D		ate:	Version: 5	
11/02/2022	01/07/2025			
Final Approval by: NIHD Board of Directors		Original Appro	oval Date: 02/15/2011	

Purpose:

To identify the priority of patients when the technologist must determine which study to perform first. In the event of conflict, final determination will be made by the radiologist.

Policy:

The priority of patient examinations follows these criteria:

- 1. Premature newborns in respiratory distress
- 2. ER Stroke Protocol Patients
- 3. Operating room patients under anesthesia
- 4. Stat requests in this order
 - a. Code Blue
 - b. ED, ICU, PACU, OB
 - c. Other in-patients
- 5. Timed exams, in progress (ex. nuclear medicine patients already injected, timed barium studies etc.)
- 6. Urgent requests for physicians waiting in the department
- 7. Fasting patients in this order
 - a. Very young or very old
 - b. Diabetic
 - c. Inpatients
 - d. Outpatients
- 8. Routine exams by order time (inpatients) or in order scheduled.

REFERENCES:

- National Library of Medicine https://pubmed.ncbi.nlm.nih.gov/26547804/
- American College of Radiology https://www.acrdsi.org/DSI-Services/Define-AI/Use-Cases/Prioritization-of-Exams-on-the-Worklist

RECORD RETENTION AND DESTRUCTION: N/A

CROSS REFERENCED POLICIES AND PROCEDURES:

1. DI timeliness for critical results

Supersedes: v.4 Diagnostic Imaging - Patient Priority



NORTHERN INYO HEALTHCARE DISTRICT CLINICAL POLICY AND PROCEDURE

Title: Fern Testing				
Owner: POCT LEAD		Department: Laboratory		
Scope: Rural Health Women's Clinic, Labor and Delivery				
Date Last Modified: 09/23/2024		: No Review	Version: 3	
	Date			
Final Approval by: NIHD Board of Directors		Original Approva	al Date: 03/15/2017	

I. PURPOSE

The fern test detects the leakage of amniotic fluid. Premature rupture of membranes (ROM) can lead to fetal infection and subsequent mortality. Detection of membrane rupture and induced labor can eliminate this risk.

II. PRINCIPLE

The fern test is based upon the ability of amniotic fluid to form a microscopic crystalline pattern suggestive of fern leaves when the fluid specimen is allowed to air dry on a glass slide. The phenomenon is due to the interaction of high concentrations of electrolytes and protein in amniotic fluid relative to other fluids that may be present in the posterior vagina.

III. SCOPE

The procedure is performed in the perinatal department by physicians, mid-level practitioners and registered nurses (RN) who have been trained and maintain competency in this moderately complex procedure.

IV. REAGENTS, EQUIPMENT AND MATERIALS

- 1. Gloves
- 2. Sterile vaginal speculum, optional
- 3. Sterile swab
- 4. Microscope
 - a. Care of the microscope provided for fern testing is important but also quite simple:
 - i. Cover the microscope when not in use primarily to protect the objectives and oculars from dust accumulation
 - ii. Clean the objective lens following each use with the lens cleaner and lens paper provided; NOTE: Do not use a dry cloth, "Kleenex" or gauze when cleaning the lens; this will generally scratch the sensitive glass surfaces
 - iii. Keep the 10x objective lens free from oil at all times
 - b. Weekly maintenance of the microscope by competent staff:
 - i. Clean dust in microscope area
 - ii. Clean oculars with lens cleaner and lens paper provided; dry with a clean, dry lens paper
 - iii. Clean stage with a suitable cleaner, e.g. tissue wipes moistened with deionized water or alcohol wet wipes, then dry with tissue wipes
 - iv. Clean condenser with lens paper and lens cleaner provided, then dry condenser with dry piece of lens paper

- v. Record date and initial of person who performed maintenance on the microscope maintenance log
- vi. Laboratory director or designee will review and sign the microscope maintenance log monthly
- vii. Maintenance logs will be kept for a minimum of two years
- c. Annual inspection/Preventative maintenance (PM) of the microscope by a specialist will be arranged by the laboratory
 - i. Document action taken with date and signature of authorized personnel
 - ii. Inspection/PM records are kept for a minimum of five years
- d. Repairs:
 - i. Necessary repairs will be performed by a service professional
 - ii. Document action taken with date and signature of authorized personnel
 - iii. Repair records will be kept for a minimum of five years
- 5. Clean microscope slide -- do NOT leave fingerprints on slide; this can cause a false positive
- 6. Commercial lens paper and lens cleaner
- 7. Tissue wipes, e.g. Kimwipes
- 8. Biohazard container

V. QUALITY CONTROL

- 1. This provider-performed microscopy procedure (PPMP) is classified as "moderately complex". Control materials are not available to monitor the entire testing process. Testing personnel are required to maintain competency.
- 2. To confirm the tester's ability to recognize the ferning crystallization pattern characteristic of dried amniotic fluid a second trained and competent RN examines the dried smear. Results of both RNs must agree and are recorded on the patient log.

VI. SPECIMEN

- 1. Acceptable specimens
 - a. Fresh vaginal pool samples collected with a sterile swab according to procedure and labeled with patient name, date of birth, date/time collected and initials of collector
- 2. Unacceptable specimens
 - a. Samples over one hour old
 - b. Unlabeled specimens
 - c. Specimens contaminated by blood, urine, cervical mucus, semen or alkaline antiseptic solutions -- these contaminates may cause false positive results (Note, the presence of meconium indicates ruptured membranes)
 - d. Specimens contaminated with lubricant or antiseptic
 - e. Specimens collected over 24 hours since rupture -- may cause false negative results
 - f. Specimens collected when volume of leakage is small -- may cause false negative result
- 3. Storage
 - a. For best results, test specimen as soon as possible after collection
 - b. Keep at room temperature until testing
- 4. Collection
 - a. Check patient ID by confirming two identifiers
 - b. Explain procedure to patient
 - c. Collect specimen according to Lippincott procedure

d. Label the swab container with patient name and date of birth, date/time of collection and collector's initials

VII. PROCEDURE

- 1. Smear a thin layer of the fluid obtained on the center portion of a clean glass microscope slide; be sure the layer is thin; spread evenly
- 2. Allow the slide to air dry for at least 5-7 minutes; do not wave or blow on the slide and do not apply heat to assist in drying
- 3. Using a microscope, examine the dried smear under low power without a cover slip
- 4. If ferning is difficult to locate, examine all fields on the slide thoroughly

VIII. RESULTS REPORTING

- 1. Positive = If present, the amniotic fluid crystallizes to form a fern-like pattern due to the relative concentrations of sodium chloride, proteins, and carbohydrates in the fluid
- 2. Negative = absence of a fern pattern indicates the absence of amniotic fluid and ROM
- Recording of Results:
 - A. Record the presence of "ferning" or "no ferning" on the "Fern Test Patient Log" with the patient's name, date of birth, date of testing, initial of testing personnel and QC results
 - B. Record the presence of "ferning" or "no ferning" on the patient's medical record chart
 - C. Include the date/time, and name of person performing the test

IX. TRAINING AND COMPETENCY

All testing personnel are trained and evaluated for competency on the fern test including pre-analysis, analysis and post-analysis components. When new test methodology or instrumentation is instituted, employees are retrained and reevaluated. The Point of care (POC) coordinator and department supervisor will develop a program for competency assessment and acceptability standards based on the training protocol, procedure manual, and departmental policies. Supervisors and managers will evaluate common group deficiencies, review current policies and procedures and take corrective action to improve performance.

A. Training and Orientation

- 1. All trainees will read the policy and procedure
- 2. Orientation/Training on the test system will be provided through demonstration
- 3. Successful orientation will be evaluated by use of a written test and initial competency assessment
- 4. Training will be provided by competent training staff
- 5. Personnel qualified to perform training is clinical staff with at least 1 year experience in fern testing and documented training and competency
- 6. Orientation and training is documented on a training checklist and filed in the POC department and kept for a minimum of 3 years; a copy of the document(s) is placed in employee personnel file

B. Competency

Competency for fern testing is assessed at the time of orientation, followed by a 6 month and 12 month evaluation and annually thereafter or as needed.

1. Competency for fern testing is assessed using all of the following six methods:

- a. Direct observation of routine patient test performance, including patient preparation, specimen handling, processing and testing
- b. Monitoring recording and reporting of test results
- c. Review of worksheets, QC records and preventative maintenance records
- d. Direct observation of performance of microscope maintenance and function checks
- e. Assessment of test performance through testing external PT samples or testing previously analyzed specimens (blind testing)
- 2. Assessment of problem solving skills by use of a written test
- 3. Independent performance with no to little additional support is considered successful
- 4. Successful performance is equal to or greater than 80% correct for the written test
- 5. Competency is assessed by a qualified designee
- 6. Personnel qualified to observe and assess competency are competent clinical staff with at least 1 year experience in fern testing
- 7. Observed competency is documented on a competency checklist and filed in the POC department and kept for a minimum of 3 years; a copy of the document(s) is placed in employee personnel file

C. Online Competency

NIHD's POC department utilizes an on-line competency challenge program hosted by the University of Washington. A link to this program along with additional instructions on how to log into the program is sent via email by the POC team. There are approximately five questions and 80% of the questions must be answered correctly to pass.

D. Proficiency testing

The POC department contracts with the Wisconsin State Laboratory of Hygiene (WSLH), a CMS approved proficiency testing program that meets regulatory requirements for variety and frequency of testing. Proficiency testing will be conducted bi-annually and consists of two images (paper and online version).

- 1. Proficiency samples are rotated among testing staff who perform patient testing
- 2. Testing personnel tests the proficiency samples the same way that patient samples are tested
- 3. The staff who perform the proficiency testing and the medical director and/or technical coordinator sign attestations documenting that proficiency samples were tested in the same manner as patient specimens
- 4. Testing personnel reports proficiency sample results the same way that patient samples are reported
- 5. Proficiency records are kept for 3 years; proficiency performance evaluations are kept for 5 years
- 6. A failure is unsuccessful performance in an event and warrants an investigation using the "Proficiency Testing Checklist for Corrective Action"; the investigation is documented and records are kept for 5 years

E. CORRECTIVE ACTION

Retraining and reassessment of employee competency must occur when problems are identified with employee performance.

A. Criteria for Remediation

Authorized training staff will perform remedial training for the following reasons:

1. When testing personnel fails an assigned proficiency test(s)

- 2. When deficiencies are being observed during competency assessment; this will be at the discretion of the authorized preceptor
- 3. When deficiencies are being observed during routine patient testing; this will be at the discretion of the supervisor
- 4. When an individual fails to comply repeatedly with testing and/or QC requirements
- 5. When testing staff is non-compliant with regulatory requirements after reasonable attempts of contact have been made by the supervisor and/or POC staff

B. Retraining and Reassessment

After determination that remediation is required, the following process will be initiated:

- 1. Department supervisor and/or director of nursing will be notified that individual will require retraining and that he/she is prohibited to perform fern testing until remediation is complete
- 2. Competent staff will review data and determine if instrument malfunction may have contributed to the problem
- 3. Authorized training staff will conduct remediation training that will include:
 - a. Review of test procedure
 - b. Review of QC logs to determine if staff performs QC correctly
 - c. Observation of specimen collection
 - d. Observation of specimen testing; if possible this will be done using specimens that the trainer observed the testing staff collect
 - e. Successful completion of a written test
 - f. Remediation will be documented and filed in the POC department and kept for a minimum of 3 years; a copy of the document(s) is placed in employee personnel file

C. Non-compliance

When it has been determined that staff is non-compliant with scheduling remediation the following steps will be taken:

- 1. Notification of department supervisor, director of nursing and/or compliance officer that the individual may not perform fern testing effective immediately
- 2. Privileges to perform testing will be revoked until staff has complied with retraining requirements

X. REFERENCES

- 1. Addison, Lois Anne. Laboratory Medicine, July 1999. P.451
- 2. University of New Mexico Health Sciences Center, Fern Test Procedure
- 3. UCSF POC Fern Test Procedure, June 2013
- 4. "Amniotic Fluid Fern Testing"; Family Birthing Suites the Finley Hospital, 20040515 S. Raymond; United Clinical Laboratories Technical Director/CIO January 1, 2007 (HR.3.10 in the Comprehensive Accreditation Manual for Laboratory and Point-of-Care Testing)

Supersedes: v.2 Fern Testing



NORTHERN INYO HEALTHCARE DISTRICT NON-CLINICAL POLICY

Title: NIHD Recruitment and Selection - Education and Experience Equivalency				
Owner: Human Resources Manager Department: Human Resources				
Scope:				
Date Last Modified:	Last Review D	ate: No	Version: 1	
11/08/2024	Review Date			
Final Approval by: NIHD Boa	rd of Directors	Original Appro	oval Date:	

PURPOSE:

The purpose of this policy is to provide guidance and outline the definitions and processes of application evaluation, and experience and education rating, during the recruitment and selection process at Northern Inyo Healthcare District (NIHD). This policy covers applications submitted for all recruitments managed by the department of Human Resources, and had no bearing or impact on any wage discussion or calculations.

DEFINITIONS:

Recruitment – the act of searching for or finding candidates to fill a vacant position.

Candidate – a person who has submitted a hiring application for a vacancy posted by NIHD

<u>Job Description – a written document that outlines essential requirements and responsibilities of a position. All positions in the District must have an accompanying job description.</u>

<u>Experience – a candidates provided work history that is most relevant or related to the position they have submitted an application to.</u>

Education – a candidates provided school history that is most relevant or related to the position they have submitted an application to. Education may consist of any level of schooling from K-12 to graduate school, trade school, professional licensure or certificate programs, or any other program that prepares attendees for employment after completion.

<u>Screening – reviewing a candidate's application, resume, and any additional provided information to ensure a candidate</u> meets the minimum requirements for a vacancy.

Application Rating Tool – a tool utilized in application screening. The screener will assign a point value to the minimum and preferred qualifications of a position based on the job description and evaluate an applicant's education, experience and certifications against said qualifications to obtain a score for passage or failure of the application on to interviews.

POLICY:

Northern Inyo Healthcare District is committed to ensuring all stages of recruitments, including the application evaluation stage, are conducted in a fair and appropriate manner, consistent with all Federal and State regulations the District is required to follow. The Human Resources Department is responsible for overseeing the recruitment and selection process at NIHD These procedures and processes will be reviewed regularly, and may be amended due to changes in regulations, recommendation of legal counsel, or under other circumstances, as needed.

In order to maintain consistency in practices, the information in this document is intended to provide guidance to any persons screening applications to determine if a candidate has achieved the minimum qualifications as provided in a

vacancies job description. Candidate qualification met through equivalent exchange of education and experience will be treated with the same weight as qualifications met through requirements as provided in the vacancy job description, but will not have any additional weight during hiring wage calculations.

If a candidate meets the position requirements for both education and experience without exchanging one for the other, no substituted education or experience will be applied.

Experience:

All experience provided by a candidate that is within the same field, and carries the same or similar title, and/or scope of duties and responsibilities is considered directly related experience. Any duration of directly related experience will be credited towards any qualification for the vacant position at an equal duration.

All experience provided by a candidate that is within the same or a related field that has related, transferrable knowledge or skills, but does not have the same title, duties, and/or responsibilities, is considered generally related experience. Any duration of general related experience will be credited towards any qualification at a prorated duration, dependent upon the duties, responsibilities, and transferability of skills and knowledge to the vacant position.

All experience provided by a candidate that is not within the same or a related field and is not similar or has no transferrable skills to the vacancy is considered unrelated experience. Unrelated experience is not considered nor credited towards any qualification for the vacant position.

For candidates who have not obtained the required level of education, directly related experience in excess of the minimum required may be substituted for the education requirements. Generally related experience and unrelated experience may not be used to substitute education requirements. The substitution may be considered at the following levels:

Directly Related Experience	Education Requirement
2 years	Associate's Degree (A.A., A.S., A.A.S, etc.)
4 years	Bachelor's Degree (B.A., B.S., B.S.N., etc.)
6 years	Master's Degree (M.A., M.S., M.P.H., etc.)

For positions that require license or certification, there will be no accepted equivalent experience credit for any education required to obtain the required license or certification. For example, a graduate degree may be required to obtain a state license for a position, a bachelor's degree and enhanced experience will not be accepted in lieu of a graduate degree as the required license would be unobtainable under that circumstance.

Education:

Education provided by a candidate that is within the same or a closely related field is considered relevant education.

Any relevant education provided by a candidate that is in excess of the required education may be deemed as equivalent to experience, and substituted as such. If a candidate has multiple degrees or certifications in excess of any requirements, only the highest level of education will be considered and applied as a substitution.

The substitution may be considered at the following levels:

Education	Experience Credit
Associate's Degree (A.A., A.S., A.A.S, etc.)	1 year
Bachelor's Degree (B.A., B.S., B.S.N., etc.)	2 years
Master's Degree (M.A., M.S., M.P.H., etc.)	3 years
All Doctorates (Ph.D., Ed.D., J.D., D.Chem, etc.)	4 years
Vocational training/certification	Dependent upon position and training/certification

REFERENCE:

RECORD RETENTION AND DESTRUCTION:

HR Records, including those relating to hiring, will be held for the life of employment or duration of the hiring process, plus 6 years

CROSS REFERENCE POLICIES AND PROCEDURES:

NIHD Recruitment and Selection

Supersedes: Not Set





NORTHERN INYO HEALTHCARE DISTRICT CLINICAL POLICY AND PROCEDURE

Title: Workplace Violence Prevention - Guidelines for Handling Threats or Violent Situations					
Owner: Chief Human Resources Officer		Department: Human Resources			
Scope: District Wide					
Date Last Modified: 11/19/2024	Last Review Date: No Review		Version: 1		
	Date				
Final Approval by: NIHD Board of Directors		Original Approval Date:			

PURPOSE:

This document summarizes guidelines for employees, volunteers, contractors, physicians and other members of the medical staff on what to do in case of threats or acts of workplace violence.

POLICY:

The purpose of this policy and procedure is to support a workplace in which violent situations are effectively addressed with a consistent procedure

Northern Inyo Healthcare District (District) is committed to providing a safe and healthful work environment for the District's patients, visitors, employees, volunteers, contractors, suppliers, members of the medical staff and members of the public. The District does not accept any act of violence or any threat of violence that occurs on District property. This prohibition against threats or acts of violence applies to all District patients, visitors, employees, volunteers, members of the medical staff, contractors, suppliers, and members of the public.

PROCEDURE:

- 1. Identifying and responding to threatening or violent individuals.
 - a. Identify potentially violent individuals.
 - i. Screening should be done by patient care workforce members using approved screening tools.
 - ii. Members of the NIHD workforce will be trained per the Workplace Violence Prevention Plan to be able to identify individuals who are potentially violent.
 - iii. If an individual who identified as violent is a patient, this must be notated on any official documentation, including patient medical records, to alert others in the workforce.
 - iv. Environmental indicators will be used to alert workforce members who are not approved to access patient records or other patient documentation.
 - v. When environmental indicators are in use, members of the workforce must speak with the Charge Nurse or House Supervisor on duty for departments inside the hospital building, or a department leader for any departments or clinics outside the hospital building, before entering the room or engaging with a patient identified as a risk.
 - vi. Individuals who are patients of the district and have been repeatedly identified as potentially violent, or repeatedly exhibited violent behaviors may have additional notation on any official documentation to alert others in the workforce

- b. Manage potentially or actively violent individuals:
 - i. Members of the NIHD workforce will be trained per the Workplace Violence Prevention Plan to be able to act in situations with potentially or actively violent individuals.
 - ii. Members of the NIHD workforce will be trained in the district Rainbow Chart and responses to each of the codes therein, including those pertaining to aggressive or violent patient;
 - Hiii. Members of the NIHD workforce will be encouraged to follow district procedures, and call Security or Emergency Services if confronted with a potentially violent situation, not try heroic action to subdue the individual, and to separate the person from patients, if possible.
 - iv. Patients who are repeatedly or exceptionally violent towards members of the district workforce may be refused all medical care excepting emergency medical care by the District or be referred to a provider or facility not associated with the District, per District practice and in compliance with all relevant local, state, and/or federal regulations.

c. If violence does erupt:

- i. Know how to protect yourself (e.g. block a punch).
- ii. Do not become the aggressor.
- iii. Stay out of range of a violent person's hands and feet, or any aid, device, or personal item that can extend the reach of the violent person.
- iv. Do not attempt to subdue the person.
- v. Keep patients away from the incident.
- vi. Per the Workplace Violence Prevention Plan, any incident of workplace violence will be investigated, and include debriefing with the effected workforce members.
- vii. Per the Workplace Violence Prevention Plan, any District employee involved in or effect by a workplace violence incident will be offered EAP and other assistance post-incident.

2. Procedure for Responding to Telephone or Written Threats

Members of the NIHD workforce will be trained to always report violent threatening or harassing behavior.

a. Telephone threats

- i. Employees are to notify their supervisor immediately. Note the time, date and telephone number at which the threat was received.
- ii. If the threat is a Bomb Threat, refer to the Rainbow Chart.
- <u>iii.</u> If the threat involves an imminent act of violence, employees must report it immediately by dialing 2400 or 71 to overhead page. Admission Staff who answer 2400 will notify Security and call any relevant or necessary codes.
- iv. If the threat is not imminent, the employee must report it to Security and their supervisor.
- v. The supervisor or Department Leader will complete an Unusual Occurrence Report

 (UOR) via the NIHD electronic system. During downtime, Workplace Violence Incident
 Report Form shall be used.

- b. Written Threats (including online or through social media outlets)
 - i. Employees must inform their supervisor immediately. Handle the written material as little as possible. Place the written material and the envelope into a larger envelope. Note the names of anyone who handled the material after it arrived.
 - ii. Follow same steps as in telephone threats referenced above in Sections 2(i)(a) 2(i)(e).

3. Procedure for Reporting Workplace Violence

- a. All employees, volunteers, contractors, physicians and other members of the medical staff are required to report immediately, any acts of or threats of violence to their supervisor, Department Head, House Supervisor, Chief, AOC, CEO, Security, or law enforcement via 9-911.
 - i. A UOR must be completed.
 - ii. No employee will be disciplined, discharged or retaliated against for reporting any threats or acts of violence.

b. Intimate Partner Violence

- i. Employees, volunteers, contractors, physicians and other members of the medical staff are encouraged to notify Human Resources if they are the victims of intimate partner violence or observe it occur in the workplace. Any such reports will be kept confidential.
- ii. If an employee, volunteer, contractor, physician and other members of the medical staff obtains a restraining order against another person and informs their Department Head or Human Resources, a description of the individual and a copy of the restraining order will be filed in Human Resources and shared appropriately to ensure a safe work environment.
- 4. Procedure for Injury from acts of Workplace Violence
 - a. Employees should obtain medical treatment, if needed, as soon as possible at the Emergency Department;
 - b. Once treatment has been received, employees must complete any work injury forms;
 - c. Either the employee or their department leadership must report the injury to Human Resources, either through direct contact or utilizing the UOR system.

REFERENCES:

Workplace Violence Prevention in Health Care Regulation (Title 8, CCR, Section 3342)

The Joint Commission Standards; EC.01.01.01, EC.02.01.01, EC.02.06.01, EC.03.01.01, and EC.04.01.01

RECORD RETENTION AND DESTRUCTION:

Human Resources records, including those relating to investigations, will be maintained for the life of employment, plus 10 years.

Records of Workplace Violence Prevention Training will be kept 6 years.

CROSS REFERENCE POLICIES AND PROCEDURES:

Workplace Violence Prevention Plan Emergency Paging System

Supersedes: Not Set

